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In many cells the hyaluronan receptor CD44 mediates the endocytosis of hyaluronan and 
its delivery to endosomes / lysosomes. The regulation of this process remains largely unknown.  
In most extracellular matrices hyaluronan is not present as a free polysaccharide but often in 
complex with other small proteins and macromolecules such as proteoglycans.  This is especially 
true in cartilage where hyaluronan assembles into an aggregate structure with the large 
proteoglycan termed aggrecan.   In this study, when purified aggrecan was added to FITC-
conjugated hyaluronan, no internalization of hyaluronan was detected.   This suggested that the 
overall size of the aggregate prevented hyaluronan endocytosis and furthermore that proteolysis 
of the aggrecan was a required prerequisite for local, cell-based turnover of hyaluronan.   To test 
this hypothesis, limited C-terminal digestion of aggrecan was performed to determine if a size 
range of aggrecan exists that was permissive of hyaluronan endocytosis.   The data demonstrate 
that only limited degradation of the aggrecan monomer was required to allow for hyaluronan 
internalization.  When hyaluronan was combined with partially degraded, dansyl chloride-
labeled aggrecan, blue fluorescent aggrecan was also visualized within intracellular vesicles.   It 
was also determined that sonicated hyaluronan that is of smaller molecular size was internalized 
more readily than high molecular mass hyaluronan.   However, the addition of intact aggrecan to 
5 and 10 second sonicated hyaluronan chains re-blocked their endocytosis while aggregates 
containing 15 second sonicated hyaluronan were internalized.   These data suggest that 
hyaluronan endocytosis is regulated in large part by the extracellular proteolytic processing of 
hyaluronan-bound proteoglycan. 
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SPECIFIC AIMS 
 
Determine the size range of manually prepared hyaluronan/proteoglycan aggregates that 
can be internalized by chondrocytes via CD44. 
 
In a state of osteoarthritis, the amount of aggrecan present in articular cartilage is 
severely diminished (1).  This is likely a result of increased matrix catabolism by chondrocytes 
that may include a sharp increase in aggrecan fragmentation and hyaluronan (HA) endocytosis 
and subsequent turnover.  Previous studies (2) have shown that HA is unable to be internalized 
via CD44 when intact aggrecan is bound.  The same study has also shown that when aggrecan is 
cleaved, leaving behind the globular G1 domain and link protein, HA can then be internalized by 
a CD44 mediated pathway.  The aim of this study is to determine the extent of extracellular 
processing (i.e. cleavage) of aggrecan needed in order for CD44 to internalize HA. 
 
 
Investigate hyaluronidase-2 activity at near neutral pH. 
 
While the previous section is focused on investigating factors such as steric hindrance 
that control HA internalization and subsequent turnover, there are investigators who believe HA 
internalization is dependent on extracellular hyaluronidase activity (3,4).  A previous investigator 
in the Knudson lab has found that hyaluronidase-2 (HYAL-2), a typically acid pH active 
hyaluronidase, can interact with CD44 at the plasma membrane (5).  Since this extracellular 
environment is not acidic, it remained unknown whether HYAL-2 had the capacity to cleave HA 
in this setting.  It was then investigated whether HYAL-2, while bound to CD44, had the ability 
	  	  
to cleave HA at various pH levels.  This could corroborate the conclusion from chapter 1 that a 
reduction in steric hindrance, whether from aggrecan or HA degradation, promotes HA 
internalization.  Additionally, since the extracellular portion of CD44 (CD44-ECTO) has been 
shown to shed from the plasma membrane, this could be a mechanism for HA cleavage in the 
interterritorial matrix.      
 
 
 
 
 
 
 
 
	  	  
CHAPTER 1:  BACKGROUND AND SIGNIFICANCE 
 
1.  Osteoarthritis 
Osteoarthritis (OA), a degenerative disease of cartilage, is one of the most common 
ailments seen in the aging population.  Recent assessments in the United States claim as many as 
50 million people have physician diagnosed arthritis (6).  OA onset becomes more prevalent with 
age; one study found that 50% of adults over the age of 65 have physician diagnosed OA (6).  
While not a fatal disease, OA symptoms include a significant decrease in quality of life, forced 
early retirement, and a major decrease in leisure activity (7).  Risks for OA include obesity, age, 
joint injury, occupations involving repetitive motions, and family history (8-10).  Late stage OA 
is identified by articular cartilage degradation, meniscus deterioration, and osteophytes (11).  
While cartilage itself does not transmit pain, bone on bone contact resulting from the cartilage 
deterioration is responsible for the joint discomfort observed in OA.  The base of the meniscus is 
highly innervated and could be an additional source of pain in individuals with late stage OA 
(12,13).  It has also been shown that knees with pain are more likely to experience cartilage 
deterioration than knees without pain (14).  The prevalence of OA is expected to rise in the 
coming years as the population ages, and rates of obesity increase.  
 
OA is a disease of dysfunction or altered metabolism of chondrocytes, the cells found in 
cartilage.  This can be a result of various biomechanical, biochemical, inflammatory, and 
immunologic factors (15).  Chondrocytes synthesize, assemble, and maintain the extracellular 
matrix (ECM) by balancing anabolic and catabolic pathways.  In early OA, both anabolism and 
catabolism are activated in an initial attempt to repair. At the same time, chondrocytes also 
produce proteolytic enzymes such as aggrecanases and matrix metalloproteinases (MMPs) that 
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result in part of the extracellular matrix degradation.  Early OA can be characterized by a loss of 
proteoglycan (PG) from the cell-associated matrix, while the surrounding inter-territorial matrix 
appears normal.  More advanced stages of OA will show a complete breakdown of the collagen 
framework, thus giving rise to the physical deterioration of cartilage to reveal the underlying 
subchondral bone (Figure 1).   
  
OA does not just affect the articular cartilage, but rather the entire articular joint 
including thickening of the subchondral bone, osteophyte formation, synovial inflammation, and 
deterioration of ligaments and meniscus.  The earliest sign of OA can be seen in parts of the 
cartilage experiencing the greatest mechanical stress (16).  At these sites, the chondrocytes will 
“awaken” from their relatively quiescent state to proliferate to form clusters of cells and increase 
production of catabolic and anabolic matrix components (17).  These events are an attempt by 
chondrocytes to repair the damaged cartilage.  The problem is that this repair process is unable to 
reproduce the same functional cartilage that is made in initial development.      
 
Current treatments for OA try to manage pain, prevent disease progression, minimize 
disability, and improve quality of life (18).  While there is no cure for OA, there are many 
options for treatment including:  weight loss, exercise, physical therapy, assistive devices, and as 
a last resort, surgery.  While there are many risk factors that can cause the onset of OA, obesity is 
the most prominent, and luckily, the most treatable factor.  Various studies have shown a 
significant improvement in joint function and joint pain when obese patients were placed on a 
reduced caloric and exercise routine (19).  This suggests that biomechanical and metabolic 
mechanisms play a role in joint health.  Physical therapy is an additional treatment option for OA 
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patients that do not respond to a diet and exercise routine (20).  This treatment method can be 
used to target a specific body part (i.e. knee) and can be customized to a patient’s individual 
needs.  Assistive devices such as canes and knee braces have been proven to manage OA 
symptoms by increasing stability of the affected joint (21-23).  Surgery is the only option for 
treating advanced stages of OA, which causes severe disability and pain.  Total joint arthroplasty 
and joint lavage and debridement can be performed to alleviate pain and increase joint 
functionality (24,25).  Surgery should be a last resort for OA patients, as it is the most invasive 
and introduces complications such as prosthesis rejection and infection.    
 
 
2.  Articular cartilage 
Cartilage is a specialized connective tissue composed of a prominent extracellular matrix 
and a sparse cell population.  Articular cartilage is found on the ends of long bones that are in 
direct contact with the other bones in a joint.  The major task of this particular kind of cartilage is 
to act as a shock absorber for the body during movement and strenuous activity and to reduce the 
friction between articular surfaces.  Water, collagen, and proteoglycans are the main components 
of the matrix and impart its unique characteristics.  Cartilage also contains hyaluronan (HA), a 
nonsulfated glycosaminoglycan made of repeating units of N-acetylglucosamine and D-
glucuronic acid.  Cartilage lacks vasculature, innervations, and cell-cell contact.  These 
characteristics make cell-matrix interactions crucial for chondrocytes to “sense” changes in the 
environment in an effort to maintain homeostasis of the tissue (26).  Articular cartilage is 
organized into four zones from superficial to deep, with each zone possessing distinctive 
characteristics.  The superficial zone is composed of flattened chondrocytes, abundant collagen 
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running parallel to the surface, and low levels of proteoglycan.  Looking at zones deeper, the 
chondrocytes become more rounded and the extracellular matrix becomes less hydrated.  The 
middle zones contain abundant proteoglycan and randomly arranged collagen.  The deepest zone 
contains calcified cartilage that separates the articular cartilage from the underlying subchondral 
bone and radially arranged collagen.  The composition of the collagen network is complex and 
variable throughout the different regions of the cartilage matrix.  Collagen type II, IX, and XI are 
found in the interterritorial matrix, while the pericellular matrix contains collagen type VI, 
fibromodulin, and matrilin-3. 
 
2.1 The cellular component of articular cartilage 
Chondrocytes are the cellular component of cartilage that accounts for approximately 5% 
of the total mass.  Though a minor component, chondrocytes are responsible for the synthesis 
and homeostasis of the entire tissue.  Chondrocytes have different properties throughout the 
various regions of the cartilage matrix.  Superficial zone chondrocytes produce lubricin, a 
glycoprotein, that provides boundary lubrication and functions in conjunction with HA to reduce 
friction in the joint (27).  Chondrocytes in the middle zone synthesize a large amount of 
proteoglycan, namely aggrecan (28).  The middle zone is also rich in type II collagen, where it 
has a half-life of 117 years (29).  The chondrocytes in the calcified cartilage, the deepest zone, 
are hypertrophic and show signs of vascularization and innervation from the subchondral bone 
(30).   Plasma membrane receptors for extracellular matrix components are one mechanism for 
chondrocyte-matrix interaction and matrix organization (31).  CD44, a single pass trans-
membrane protein, is the principal cell surface receptor for HA in chondrocytes.  CD44-HA 
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interactions provide a means for cell-matrix communication, promote the ability of chondrocytes 
to sense changes in the extracellular matrix, as well as play a role in regulation of extracellular 
matrix metabolism, a main function of chondrocytes.  The endocytosis of HA by CD44 is a 
mechanism for the turnover of HA, which results in tissue homeostasis. 
 
2.2.  The extracellular matrix of articular cartilage 
The extracellular matrix (ECM) comprises roughly 95% of the tissue in hyaline cartilage 
and is comprised of water, proteoglycans, and a network of collagen fibers.  HA is the core 
filament of the proteoglycan aggregate and is responsible for retaining bound aggrecan 
monomers to the chondrocyte (Figure 2).  HA is synthesized by hyaluronan synthase 2, which is 
located in the plasma membrane of chondrocytes (32).  Aggrecan is the principal cartilage 
proteoglycan and is composed of a core protein with numerous chondroitin sulfate and keratan 
sulfate side chains.  The globular G1 domain of the core protein binds to HA and is reinforced by 
a bi-functional binding protein called link protein.  Chondroitin sulfate and keratan sulfate are 
sulfated glycosaminoglycans which possess a significant negative charge (Figure 3A).  This 
negative charge attracts a large amount of water molecules that are drawn into the sulfated 
glycosaminoglycans, producing a swelling pressure on the collagen network to generate a 
compressive resilience. When a force is put on cartilage (e.g. walking), the glycosaminoglycan 
chains compress, forcing the water out of the glycosaminoglycans, thus condensing the negative 
charges into a smaller area (Figure 3B).  Placing so many negative charges so close together 
creates a repulsion force that springs the sulfated glycosaminoglycans away from each other 
when the force is removed from the joint, thus drawing the water back in.  This phenomenon is 
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referred to as the Donnan effect and is what gives cartilage its shock absorbing capabilities and 
ability to cushion the joints (33).  Collagen forms a scaffolding that helps organize and restrain 
aggregates, as well as imparts tensile strength to cartilage (34). 
 
3.  Aggrecan 
Aggrecan is a proteoglycan consisting of a core protein decorated with sulfated 
glycosaminoglycans (Figure 4).  The core protein includes three globular domains and two 
extended domains.  The N-terminal globular G1 domain binds HA and shares homology with 
link protein (35).  A short interglobular domain (IGD) separates the globular G1 domain from the 
globular G2 domain, which has no known function (36).  The section of core protein between the 
globular G2 and G3 domain is an extended region decorated with keratan sulfate and chondroitin 
sulfate (37,38).  The C-terminal G3 domain is involved in intracellular transportation and 
subsequent secretion of the proteoglycan (39).  The G3 domain is so vital for secretion that core 
protein containing a mutated G3 domain accumulates in the ER lumen (40).  The G3 domain has 
a C-lectin domain that has been implicated in binding carbohydrates (41), tenascin-R (42), 
tenascin-C (43,44), fibrillin-1 (45), fibulin-1 (46), and fibulin-2 (47).  These ligands to the C-
lectin domain may play an important role in extracellular matrix interactions. 
 
3.1  Aggrecan synthesis 
Aggrecan synthesis begins by being translated into the endoplasmic reticulum where the 
globular domains are monitored for proper folding by chaperone proteins (48).  The site of future 
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sulfated glycosaminoglycan chains are formed by the production of a linkage region when a 
xylosyltransferase catalyzes the addition of a UDP-xylose to an available serine residue on the 
core protein (49).  The glycosaminoglycan binding region, between the globular G2 and G3 
domains, consists of approximately 120 serine-glycine repeats, though not all are destined to be 
xylosylated (50).  Upon xylosylation of a serine residue, the linkage region is further extended by 
galactosyltransferase I, which catalyzes the addition of a galactose to the xylose (51).  The final 
stage of formation of the linkage region is the addition of another galactose, catalyzed by 
galactosyltransferase II (52).  Upon transfer to the Golgi apparatus, the core protein goes through 
post-translational modification to elongate the glycosaminoglycan chains from the linkage 
region.  This occurs by the alternating addition of N-acetylgalactosamine and glucuronic acid 
residues (53,54).  As many as 30 keratan sulfate chains and 100 chondroitin sulfate chains can 
extend from a single core protein (55).  It is currently unknown exactly how elongation of the 
keratan sulfate and chondroitin sulfate chain is terminated.  Possible explanations include a loss 
of affinity of the elongation enzymes for acceptors or the glycosaminoglycan chain being 
“capped” by a nonreducing N-acetylgalactosamine 4-sulfate, which will not allow a subsequent 
glucuronic acid to bind (54).  The completed aggrecan monomers are packaged into secretory 
vesicles and secreted out of the cell by exocytosis (56).  Upon entering the extracellular matrix, 
aggrecan will form a highly structured aggregate complex with HA (57) and link protein (58).  
Each intact aggrecan monomer is ~ 2.5 x 106 Da (55).  Additionally, a single HA chain can be 
decorated with more than 100 aggrecan monomers as well as link protein (33).  The aggregation 
of aggrecan with HA is crucial for retaining aggrecan in the extracellular matrix.  Unbound 
aggrecan has been shown to diffuse out of the cartilage matrix especially when the cartilage is 
under compression.     
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3.2.  Aggrecan turnover 
Aggrecan is constantly being fragmented and turned over in the extracellular matrix of 
articular cartilage by enzymes produced from chondrocytes.  Pathologic conditions such as 
osteoarthritis arise when the rate of catabolism overcomes the rate of anabolism.  Two families 
of enzymes responsible for this depletion of aggrecan are matrix metalloproteinases (MMPs) 
such as MMP-1, MMP-3, MMP-8, and MMP-13 (59-63) and enzymes in a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTSs) family such as ADAMTS-1, 
ADAMTS-4, and ADAMTS-5 (64-66).  Studies involving ADAMTS-5 knockout mice have 
shown that this enzyme is responsible for the majority of PG turnover in mouse OA (67).  In 
humans, it has been suggested that LRP-1, a low-density lipoprotein receptor-related protein, 
regulates ADAMTS-5 activity by internalizing the enzyme, thus preventing extracellular 
aggrecan degradation (68).  In a state of OA, the protein levels of LRP-1 are significantly 
decreased, thus reducing internalization and subsequent turnover of ADAMTS-5, allowing 
ADAMTS-5 to accumulate in the ECM and cleave aggrecan.  Enzymes in the ADAMTS and 
MMP families cleave aggrecan in the IGD at unique sites, thus creating unique neoepitopes 
indicative of the specific enzyme family.  Upon a single proteolytic cleavage of aggrecan, two 
subsequent aggrecan fragments are formed.  The aggregating fragment is the N-terminal end 
containing the globular G1 domain that remains bound to HA.  The nonaggregating C-terminal 
fragment containing the globular G3 domain is free to diffuse out of the cartilage to be turned 
over in the synovial fluid.  While the nonaggregating fragments can be used as biomarkers for 
OA (69,70), the aggregating fragments remain in the cartilage matrix (71).  With time, the 
aggregating aggrecan fragment can undergo further proteolytic cleavage until only the globular 
G1 domain remains bound to HA, which is resistant to cleavage.   
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4.  Hyaluronan 
HA was first characterized in 1934 by Karl Meyer and John Palmer by being purified 
from bovine vitreous humor (72).  They found HA to be a mucopolysaccharide composed of 
repeating units of N-acetylglucosamine and D-glucuronic acid.  This seemingly simple 
carbohydrate has been indicated in a variety of functions such as maintaining tissue hydration, 
extracellular matrix assembly, tumor development, inflammation, and various roles in cell 
mitosis, migration, and metastasis (73-75).  HA is an extremely hydrophilic molecule that 
attracts large amounts of water to provide hydration and lubrication to joints and muscles.  HA is 
also found in the connective tissue elements such as vitreous humor, synovial fluid, and 
umbilical cord and organs such as skin, lung, brain, and kidney.  HA is not only ubiquitous 
throughout the body, but also evolutionarily conserved across all mammalian species, suggesting 
its biological importance (76). 
 
4.1.  Hyaluronan synthesis 
While most glycosaminoglycan synthesis takes place in the Golgi apparatus, HA is 
uniquely synthesized by membrane proteins called hyaluronan synthases (HAS) (77).  There are 
three synthases called HAS-1, HAS-2, and HAS-3 that are responsible for all HA production in 
vertebrates (78).  The HAS gene family has high homology in its amino acid sequence 
throughout different species (79,80).  Two types of membrane domains exist in the HAS protein:  
transmembrane domains and membrane associated domains that do not penetrate the membrane.  
These domains not only synthesize HA, but also form a pore in the plasma membrane through 
which the newly synthesized HA is transported to the extracellular space.  HA is synthesized by 
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the alternating addition of activated nucleotide sugars on the non-reducing end:  UDP-N-
acetylglucosamine and UDP-glucuronic acid (80).  The HA chain is extruded out of the cell as it 
is being synthesized where it can be released into the extracellular matrix, or be retained at the 
cell surface (81).  Another characteristic of HA that sets it apart from other glycosaminoglycans 
is that it is not modified by sulphotransferases, fucosyltransferases, or N-acetyl transferases.  
While the exact mechanism that controls the termination of HA synthesis is currently unknown, 
there are many possible explanations.  It has been suggested that hyaluronan synthases can run 
out of substrate, lose stability, or even be overcome by the repulsion force presented from the 
newly synthesized HA chain.   
 
 The lack of a definitive termination mechanism for HA synthesis has resulted in HA 
existing in a wide range of sizes.  Other factors that can alter the size of HA include extracellular 
proteolytic processing (3,4), free radical degradation (82), and cross-linking (83).  The diverse 
functions of HA can be attributed to the various molecular sizes of HA.  For example, the size of 
HA bound to cancer cells has an important effect on tumor growth and metastasis.  Studies have 
found that tumor growth can be perturbed by the introduction of HA filaments as small as 12 
monosaccharides long (84).  This occurs because the low molecular weight HA competes with 
the high molecular weight HA for binding to CD44, thus inhibiting high molecular weight HA 
from binding to the tumor cell.  It has previously been found that high molecular weight HA 
binding is associated with tumor growth and metastasis (85).  By preventing high molecular 
weight HA from binding to tumor cells, the growth and metastasis will be inhibited.  In 
angiogenesis studies, high molecular weight HA has been found to be antiangiogenic, while HA 
around 20 monosaccharides in length promote angiogenesis (86,87).  High molecular weight HA 
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is also beneficial in certain instances; in a study investigating cartilage deterioration in early OA 
models, intra-articular injection of high molecular weight HA (1,900 kD) was more effective at 
inhibiting cartilage degeneration than HA of 800 kD size (88).  These are just some examples of 
how HA can exert drastically different effects depending on its size.       
 
4.2.  Hyaluronan turnover 
HA turnover in the human body can take place locally in chondrocytes by CD44 
internalization, or systemically by lymph nodes.  HA can be degraded by hyaluronidases 
(HYALs) (89,90) upon endocytosis in cells and a small fraction of HA is known to be degraded 
by free radicals (91).  HA is cleared from the blood by binding to the HA receptor for 
endocytosis (HARE) (92).  Upon internalization into lymphocytes, HA is localized in endosomes 
and cleaved by HYALs and exoglycosidases (2,89,93).  HA can also interact with other tissue 
specific cell surface receptors such as layilin, RHAMM, LYVE-1, and CD44 (94-98).  CD44 is 
the primary cell surface receptor for HA in articular cartilage (94).  This interaction is very 
important, as cartilage HA is immobile and is unable to access the circulatory system to be 
turned over by lymph nodes.  This unique turnover pathway of HA has caught the attention of 
many cartilage researchers and has been the source of many investigations.   
 
HA in articular cartilage is typically a very large, high molecular weight macromolecule 
in the size range of 2-10 x 106 Da (99).  An early question was whether an intact, high molecular 
weight HA chain could be internalized by chondrocytes.  To address this question, a previous 
investigator incubated rat chondrosarcoma (RCS) cells and bovine articular chondrocytes with 
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HA metabolically labeled with tritium ([3H]HA) (8).  The RCS cells and bovine articular 
chondrocytes were first pre-treated with testicular hyaluronidase to remove the endogenous HA-
rich cell-associated matrix.  After allowing 24 hours for [3H]HA binding and internalization, the 
cell surface bound fraction was removed by protease treatment and the intracellular fraction 
isolated.  The resulting cell lysate was then applied to a CL-2B gel-filtration chromatography 
column.  The intracellular pool of [3H]HA was composed of two peaks; one peak in the void 
volume and another in the total volume.  The void volume for a CL-2B column contains 
macromolecules which are > 2 x 106 Da.  This data illustrated that chondrocytes have the 
capability to internalize high molecular weight HA chains. 
 
The presence of a very low molecular weight intracellular pool, in the total volume, 
suggested that the internalized [3H]HA had been degraded.  To determine whether this 
degradation might be due to localization within lysosomes, the previous experiment was 
repeated, but included pretreatment of the chondrocytes with the lysosomotrophic agent, 
chloroquine.  Chondrocytes pre-treated with chloroquine showed a shift in intracellular [3H]HA 
to higher molecular mass HA, and a decrease of [3H]HA in the total volume fractions (33).  This 
additional data suggests that internalized HA is present in two intracellular pools and that these 
two pools represent localization of HA within endosomes and lysosomes for degradation.  This 
data does not exclude the possibility that HA is perhaps processed or partially degraded 
extracellularly (100) as occurs in the catabolism/degradation of aggrecan monomers (100,101).  
These studies suggest that prior reduction of HA size is not required for HA internalization.  The 
data also show that HA can be processed intracellularly by low pH-dependent mechanisms such 
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as within lysosomes (102-104).  This illustrates a turnover pathway for high molecular weight 
HA bound to chondrocytes in articular cartilage. 
 
The HA in articular cartilage does not exist as free, unoccupied glycosaminoglycan 
chains.  Rather, HA contains many bound proteins, proteoglycans (PGs), and remnants of 
degraded PGs (17).  To determine whether these bound molecules could be co-internalized with 
HA via CD44, a previous investigator performed a series of internalization studies on bovine 
articular chondrocytes using exogenous HA conjugated with fluorecein (FITC-HA).  Bovine 
articular chondrocytes showed the capacity to bind and co-internalize FITC-HA decorated with a 
75 kD PG remnant (105).  Similar studies were performed using FITC-HA decorated with more 
native PG fragments called hyaluronan binding proteins (HABP) namely, 72 kD G1-ITEGE and 
60 kD G1-DIPEN (106).  From these experiments, it was concluded that chondrocytes have the 
ability to bind and internalize exogenous HA decorated with proteins that were at least 75 kD in 
size (2) (Figure 5B).  To determine whether intact aggrecan monomers could be co-internalized 
with HA via CD44, Embry et al. decorated FITC-HA with purified aggrecan monomers from 
bovine articular cartilage (107) (Figure 5A).  The resulting fluorescently labeled HA/aggrecan 
aggregate was added to a culture of bovine articular chondrocytes pretreated with Streptomyces 
hyaluronidase.  The aggregate appeared able to bind to the cell surface, as illustrated by the 
formation of a fluorescent pericellular matrix coat.  However, it was unable to be internalized by 
the chondrocytes.  Since HA decorated with aggrecan fragments can be internalized while HA 
decorated with intact aggrecan cannot, it then became necessary to combine the two complexes 
to observe the effect on binding and endocytosis.  HA/aggrecan/HABP complex was added to a 
culture of bovine articular chondrocytes pretreated with 5 units/ml Streptomyces hyaluronidase.  
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This complex was able to bind to chondrocytes in the same manner as HA/HABP and 
HA/aggrecan; however, no internalization was observed while intact aggrecan monomers were 
bound to HA.  It was only after the cell-bound HA/aggrecan/HABP complex was trypsinized that 
it could be internalized, much like the HA/HABP complex.  This suggests that steric hindrance, 
or perhaps charge density presented by bound intact aggrecan, prevents HA internalization. 
 
4.3.  Neutral pH hyaluronidase activity 
While there has been extensive investigations exploring the turnover pathway of cell-
bound HA (108-110), the function of extracellularly bound hyaluronidase enzymes has remained 
elusive.  Furthermore, the exact turnover pathway of HA in the interterritorial matrix, while 
minimal, is unknown as well.  HA in the cartilage ECM accumulates in mature, healthy tissue 
(111).  This suggests a lack of a turnover pathway for HA not bound to CD44.     Previous 
studies have also found that HA in the ECM, not bound to cells, decreases in size over time 
(112,113).  The cause of this small amount of HA catabolism is still unknown but some 
investigators claim it is the result of free-radical mechanisms (82,114,115).  A previous fellow in 
the Knudson lab has found an alternative mechanism to explain interterritorial HA fragmentation 
as well as possible pericellular HA turnover. 
 
HYAL-2 is an acid-activated enzyme that cleaves high molecular weight HA down to 20 
kDa fragments (90,116).  This enzyme has traditionally been thought to bind cells by a 
glycosylphosphatidylinositol anchor (117), but recent studies have found that it can also bind 
CD44 in the chondrocyte plasma membrane (4,118).  This interaction allows HYAL-2 to be 
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internalized and colocalize with CD44 and HA in low pH vesicles, where HYAL-2 shows high 
enzymatic activity.  While HYAL-2 is known as a lysosomal enzyme, the discovery that it 
interacts with plasma membrane receptors have opened the possibility that HYAL-2 can exhibit 
enzymatic activity in the extracellular environment, in near neutral pH.  One investigator found 
that HYAL-2 can cleave HA at a pH between 6.0-7.0 only when CD44 is also present in the 
plasma membrane (3).  Another investigator has found that HYAL-2 binds CD44, and this 
interaction is maintained upon shedding of the CD44 ECTO domain (5).  This would suggest that 
HYAL-2/CD44-ECTO complex is able to be shed from the plasma membrane and diffuse 
through the ECM to cleave HA in the interterritorial domain or remain bound to the cell and 
cleave pericellular HA (Figure 6).   
 
To test this hypothesis, an assay was developed that would display HYAL-2 enzymatic 
activity while maintaining the HYAL-2/CD44 domain interaction.  Previous enzymatic assays 
have been performed under reducing conditions, thus dissociating HYAL-2 from CD44.  In this 
unbound state, HYAL-2 was only enzymatically active when at pH 3.7, like that found in a 
lysosome (119).  In this study, agarose gels were used to detect HA cleavage by HYAL-2/CD44 
complex that had been isolated by coimmunoprecipitation, and then incubated at various pH 
levels with FITC-HA.  Additional studies used sonicated membrane fractions of cells containing 
HYAL-2 and CD44 to visualize HYAL-2 activity using an ELISA assay.       
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5.  CD44 
CD44 is a single pass transmembrane glycoprotein involved in cell growth, survival, 
differentiation, and motility.  The extracellular, amino terminal globular domain of CD44 shares 
homology with link protein and the aggrecan globular G1 domain (120).  This attribute of CD44 
makes it an important cell surface receptor for HA (121-123).  Additionally, a single HA 
filament is capable of binding multiple CD44 receptors, thus increasing avidity and the 
likelihood of being internalized.  While it has been previously determined that aggrecan globular 
G1 domain and link protein can bind and be internalized by bovine articular chondrocytes (2); it 
was unclear whether this was dependent on CD44.  This question led to a study that incubated 
bovine articular chondrocytes with unlabeled HA decorated with biotinylated HABP (bHABP) 
(106).  This experiment took place in the presence of dilute Streptomyces hyaluronidase to 
prevent HA from binding to the cell surface.  From this treatment, it appeared that bHABP is 
unable to bind or be internalized by the cell.  To test the effect CD44 has on the binding and 
endocytosis of HA labeled with bHABP, chondrocytes were transfected with CD44∆67.  This 
isoform of CD44 lacks the 67 amino acids located on the C-terminal side, which accounts for 
nearly the entire cytoplasmic domain.  It has been previously shown that the cytoplasmic domain 
of CD44 is required for CD44 to bind and internalize HA (102).  This transfection prevented 
chondrocytes from binding and internalizing HA tagged with bHABP.  Previous investigators 
have been able to prevent HA internalization by treating cells with anti-CD44 blocking 
antibodies (106), or using Cd44-/- chondrocytes or fibroblasts (124).  It appears, based on these 
investigations, that bHABP and HA are dependent on CD44 for internalization into 
chondrocytes. 
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Since CD44 has been implicated in the binding and internalization of HA in articular 
cartilage, an effort has been made to establish how this process is regulated.  One study 
investigated the role that lipid rafts may play in governing CD44 mediated internalization of HA 
(125).  Lipid rafts are hydrophobic microdomains in the cell plasma membrane rich in 
cholesterol and sphingolipids.  Their functions include: signal transduction, apoptosis, and 
receptor endocytosis (126,127).  This study found that palmitoylation of two cysteine residues in 
the transmembrane and cytoplasmic domains was required to allow CD44 to enter a lipid raft.  
Upon entering the lipid raft, CD44 and bound HA was able to be internalized for turnover.  
Blocking CD44 from entering the lipid raft did not inhibit HA binding, but did inhibit 
internalization.  This suggests a possible mechanism that regulates the ability of CD44 to 
internalize HA.  What still remains unknown are the mechanisms that regulate HA 
internalization by CD44.    
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6.  SUMMARY 
 
Hyaluronan (HA) is responsible for the retention of the proteoglycan aggrecan in articular 
cartilage.   Within the extracellular space, aggrecan is organized as a multicomponent aggregate, 
composed of aggrecan monomers bound to a core filament of HA and stabilized by association 
of link proteins (16).  The HA/aggrecan/link protein complex is retained at the chondrocyte cell 
surface either via connections with an HA synthase or bound to CD44 (17,18).  All three of these 
components of the aggrecan aggregate constantly undergo turnover in healthy and osteoarthritic 
cartilage.  For example, one of the early events associated with osteoarthritis is the pronounced 
loss of aggrecan from the cartilage (16).  Aggrecan turnover occurs extracellularly due to 
cleavage of the core protein by endoproteinases termed aggrecanases as well as matrix 
metalloproteinases (19-21). C-terminal, chondroitin sulfate-rich fragments of aggrecan are lost 
from the cartilage by release into the synovial fluid (27,28).   
 
In addition to aggrecan, a significant loss of HA is observed in human OA cartilage (29). 
In our previous studies, cultured explants of human articular cartilage treated with interleukin-1α 
displayed a loss of HA within the superficial and upper middle layers of cartilage—the same 
layers where aggrecan loss also occurred (32).   We have demonstrated that the other residual 
components of the aggrecan aggregate, namely the HA, together with bound aggrecan globular 
G1 domains, and presumably link protein, are internalized by chondrocytes via a CD44-mediated 
mechanism (4,7-9).   This was illustrated by blocking the endocytosis of HA and aggrecan 
globular G1 domains (G1-ITEGE and G1-DIPEN) by pre-treatment of chondrocytes with anti-
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CD44 blocking antibodies (8), CD44 siRNA or a CD44-dominant negative construct (9).   
Additionally, no internalization of HA and G1-ITEGE was observed in murine Cd44-/- 
chondrocyte or fibroblast cultures (9).    
 
What remains unknown is whether the turnover of aggrecan (an extracellular, proteolytic 
processing event) and the turnover of HA (internalization and intracellular degradation) are in 
any way coordinated.   Previous studies using radiolabeling of bovine articular cartilage explant 
cultures demonstrated that newly synthesized HA and proteoglycan (aggrecan) had nearly 
identical half-lives of ~13-25 days (15,33).    How these turnover rates could be similar given the 
differing mechanisms involved remained to be clarified.  We have shown previously, using 
bovine chondrocytes, that the addition of full-size aggrecan to HA limited the ability of the HA 
to be internalized (8).   This suggested a hypothesis that HA endocytosis occurs only after a 
sufficient degree of degradation of the large aggrecan monomers has occurred.  In other words, 
there may be an overall size requirement for HA aggregates, that is permissive (or non-
permissive) for HA endocytosis.   In this study, HA endocytosis was examined in the presence 
and absence of bound aggrecan monomers of decreasing size.  Partially degraded aggrecan 
species were obtained following limited, controlled C-terminal proteolysis of purified aggrecan 
monomers or digestion of HA/aggrecan aggregates.  This project demonstrates that the capacity 
for HA endocytosis by chondrocytes is dependent on changes in size of the aggrecan decorating 
the HA. 
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Figure 1:  Donor samples from total knee replacement patients 
Healthy articular cartilage is seen as a smooth, intact surface which functions in shock absorption 
and provides a low friction surface.  Late stage OA is seen as a complete breakdown of the 
cartilage matrix, revealing the underlying subchondral bone.  Joint pain is a result of the bone on 
bone contact in the articulating joint. 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   22	  
 
 
 
 
 
 
 
 
 
 
	  	   23	  
Figure 2:  The extracellular matrix of cartilage 
This figure illustrates the organization between chondrocytes and the extracellular matrix in 
articular cartilage.  HA is synthesized through the plasma membrane by hyaluronan synthase 
(HAS) where it can be retained at the plasma membrane by interaction with CD44.  Once in the 
extracellular matrix, HA can be decorated with various proteoglycans such as aggrecan.  Link 
protein reinforces this interaction by its ability to bind HA and aggrecan globular G1 domain 
(image modified from Knudson and Knudson 2005).   
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Figure 3:  Donnan effect 
Figure depicts the mechanism that allows articular cartilage to act as a shock absorber.  A 
diagram of an aggrecan monomer is represented using chondroitin sulfate chains as brown lines, 
aggrecan core protein as black lines, and negative charges as red dashes.  Panel A depicts an 
aggrecan monomer that is not under a compressive force.  The negative charges repel each other, 
thus pulling the glycosaminoglycan chains away from each other.  When a force is applied to 
cartilage, the aggrecan will be compressed, thus forcing the negative charges into close 
proximity with each other (panel B).  A strong repulsion force is thus created causing the 
aggrecan monomer to spring back to its original configuration (panel A) when the force is 
removed.  
 
 
 
 
 
 
 
 
 
	  	   26	  
 
 
 
 
 
 
 
 
 
 
	  	   27	  
Figure 4:  Aggrecan structure 
Figure depicts an intact aggrecan monomer bound to HA.  The N-terminal globular G1 domain 
(G1) binds HA.  The globular G2 domain has no known function (G2).  The extended region 
between the globular G2 and the C-terminal globular G3 domain (G3) contains regions rich in 
keratan sulfate (KS) and chondroitin sulfate (CS).  Aggrecan core protein is represented by the 
entire black line. 
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Figure 5:  The effect of bound proteoglycans on HA internalization 
Studies have shown that when HA is decorated with intact aggrecan monomers, it can bind 
chondrocytes, but is unable to be internalized by a CD44 dependent pathway (panel A).  When 
HA is decorated with extensively degraded aggrecan monomers (panel B), the HA is also able to 
bind chondrocytes but can be internalized.  These observations were an initial indicator that 
aggrecan may play a role in regulating HA internalization and subsequent turnover.  
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Figure 6:  Possible mechanism for CD44-ECTO/HYAL-2 shedding 
Figure depicts possible mechanism for HYAL-2 interaction with CD44 at the plasma membrane.   
This interaction would anchor HYAL-2 to the plasma membrane, thus potentially cleaving cell 
bound HA.  Additionally, the extracellular domain of CD44 can be enzymatically cleaved 
(yellow lightening bolt), thus causing shedding of the CD44-ECTO/HYAL-2 complex from the 
chondrocyte plasma membrane and possibly cleaving HA in the interterritorial matrix at a near 
neutral pH range. 
 
 
 
 
 
 
 
 
 
	  	  
CHAPTER 2:  MATERIALS AND METHODS 
 
1. Purifying aggrecan monomer 
1.1.  Cesium chloride gradient ultracentrifugation 
Full thickness slices of bovine articular cartilage were excised from 18-24 month bovine 
metacarpophalangeal joints obtained from a local abattoir (39). The cartilage was frozen in liquid 
nitrogen, ground to a powder and extracted in dissociative buffer consisting of 4.0 M guanidine 
HCl, 0.01 M EDTA, and 0.05 M sodium acetate, pH 5.8 (40,41). After gentle stirring at 4 oC for 
24 h, the solution was centrifuged at 13,000 X g and brought to a final density of 1.5 g/ml by the 
addition of 0.5452 g CsCl/ml. Samples were centrifuged at 100,000 X g for 48 h at 4 oC in a 
Beckman 50.2Ti rotor. Upon completion, the bottom fifth of each centrifuge tube was isolated, 
dialyzed against water for three days, and lyophilized. 
 
1.2.  DEAE ion exchange chromatography  
 Proteoglycan was extracted from bovine articular cartilage using 4 M guanidine HCl, 
dansylated (see 2.3), and then dialyzed against water to then be purified using ion exchange 
chromatography using diethylaminoethyl (DEAE) resin beads (GE Healthcare, Piscataway, NJ).  
The beads were packed into a glass column and rinsed with 0.2 M NaCl until equilibration was 
observed using a Cond 6+ conductivity meter (Eutech Instruments, Singapore).  The dansylated 
aggrecan solution was then added to the column and washed through with 0.2 M NaCl until no 
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UV fluorescence was detected in the eluant using a fluorimaging system (Chemi-Doc, Bio-Rad, 
Hercules, CA).  The aggrecan was then dissociated from the DEAE beads using 4M guanidine 
HCl and eluted from the column.  The purified aggrecan was then dialyzed against water and 
lyophilized. 
 
1.3.  HA affinity chromatography 
A mass of 250 mg of HA (1.2-1.8 MDa, Lifecore Biomedical, Chaska, MN) was 
dissolved in 250 ml of 0.15 M NaCl, 0.1 M NaC2H3O2, pH 5.0.  The HA solution was combined 
with 31 ml Sepharose 4B (GE Healthcare, Piscataway, NJ) in water at pH 4.5.  Next, 0.59 grams 
of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (Sigma-Aldrich, St. Louis, MO) was 
added to the mixture at room temperature and the pH was held at 4.5 for 2 hours using 0.1 M 
HCl.  To block any unbound sites on the Sepharose beads, 4.2 ml of acetic acid was added and 
the solution was allowed to sit at room temperature for 6 hours.  The gel was then washed by 
decanting with 420 ml of (a) 1 M NaCl, (b) 0.1 M Tris-HCl, 1 M NaCl (pH 8.1), (c) 0.05 M 
formate buffer (pH 3.1) and (d) water.  The gel slurry was finally transferred to 0.5 M NaC2H3O2 
(pH 5.7) for storage as HA-substituted Sepharose 4B until use.   
  
Full thickness slices of bovine articular cartilage were excised from 18-24 month bovine 
metacarpophalangeal joints obtained from a local abattoir (Sims, NC).  The cartilage was frozen 
in liquid nitrogen, ground to a powder and extracted in dissociative buffer consisting of 4.0 M 
guanidine HCl, 0.01 M EDTA, and 0.05 M sodium acetate, pH 5.8 (40,41). After gentle stirring 
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at 4oC for 24 h, the solution was centrifuged at 13,000 X g for 45 minutes, supernatant dialyzed 
against water, and then lyophilized.  A total of 0.33 grams of lyophilized cartilage extract was 
dansylated (see 2.3), dialyzed against water, and then lyophilized.  The dansylated cartilage 
extract was dissolved in 18.6 ml of 4 M guanidine HCl, 0.5 M NaC2H3O2, pH 5.8.  The 
solution was then mixed with 31 ml of HA-substituted Sepharose and dialyzed against water for 
24 hours at 4oC.  The gel slurry was packed into a column and washed with 42 ml of 1 M NaCl, 
followed by 600 ml of a linear gradient of 1 to 3 M NaCl.  Washing 167 ml of 4 M guanidine 
HCl through the column at 4oC eluted the material bound to the HA-substituted Sepharose.   
 
 
2. Visualizing HA and aggrecan 
 
2.1.  Preparation of fluorescein conjugated HA  
Fluorescein conjugated HA (FITC-HA) was prepared by dissolving 50 mg of HA (1.2-1.8 
MDa, Lifecore Biomedical, Chaska, MN) in 40 ml of water, followed by the addition of 20 ml of 
dimethyl sulfoxide (Fisher Scientific).  Fluorescein isothiocyanate solution was prepared 
separately as follows, then added to HA solution:  0.5 ml DMSO (Fisher Scientific), 25 µl 
cyclohexyl isocyanide (Sigma-Aldrich), 25 µl acetaldehyde (Sigma-Aldrich), and 25 mg 
fluoreceinamine, isomer 1 (Sigma-Aldrich).  The solution was adjusted to pH 4.5 and allowed to 
incubate in the dark for 5 hours at 25oC.  After incubation, 140 ml of 100% ethanol (Ultra Pure 
USA) was added to bring the reaction solution to 70% ethanol, along with 1.3% (w/v) potassium 
acetate (Sigma-Aldrich).  The solution was allowed to sit overnight at -20oC.  The precipitated 
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FITC-HA was pelleted by centrifugation at 1,300 X g for 10 minutes at 4oC.  The supernatant 
was discarded and the resulting pellet was allowed to thoroughly dry in a dark chemical hood.  
The dried pellet was resuspended in 50 ml of phosphate buffered saline (PBS; Amresco) to bring 
to a final concentration of 1 mg/ml FITC-HA.   
 
2.2.  Preparation of biotin-HA 
 Biotinylated HA (biotin-HA) was prepared by dissolving 200 mg of high molecular 
weight hyaluronan (Lifecore Biomedical, Chaska, MN) in 50 mL of deionized water to bring to a 
final concentration of 4 mg/ml.  3.5 g of adipic dihydrazide (Acros Organics, New Jersey) was 
added to the solution and pH adjusted to 4.75 using 0.1 N HCl.  Next, 0.382 g of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide HCl (Sigma-Aldrich, St. Louis, MO) was then dissolved in 
the solution and pH adjusted back to 4.75 using 0.1 N HCl.  The reaction was allowed to proceed 
for 2 hours, and then was terminated by raising the pH to 7.0 using 1 N NaOH.  The resulting 
cross linked HA was dialyzed overnight in water, and then lyophilized.   
  
To biotinylate the hydrazido-HA, 11 mg was dissolved in 0.1 M NaHCO3 to bring the 
HA to a final concentration of 7 mg/ml.  50 mg of Sulfo-NHS-Biotin (Thermo Scientific, 
Rockford, IL) was dissolved in the solution and allowed to stir at room temperature overnight.  
Finally, the solution was diluted 10 fold in water, dialyzed overnight, and lyophilized.    
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2.3. Preparation of dansylated proteoglycan 
 Aggrecan monomer or aggregate was labeled with dansyl chloride.  Briefly, 6 mg of 
purified aggrecan monomer or aggregate was dissolved in 1 ml water. The solution was then 
mixed with an equal volume of 2 M Na2CO3 (pH 11). 5 mg of dansyl chloride (Alfa Aesar, 
Heysham, England) in 1 ml acetone was slowly added to the mixture with stirring and was 
allowed to sit at room temperature for 1 hour in the dark. The solution was then ethanol 
precipitated overnight, dried, and resuspended in media. 
 
2.4.  Agarose gel electrophoresis 
HA and proteoglycans were separated on 1% agarose gels prepared in Tris-acetate-EDTA 
buffer and cast into 10 x 15 cm trays of a MP-1015 horizontal electrophoresis apparatus (ISI 
Scientific) (44-46). Samples (15 µl) were loaded into each well with one well loaded with 5 µl of 
a 1 kb-PLUS DNA ladder (100– 12,000 bp; Thermo Fisher, Waltham, MA) for reference. 
Electrophoresis was carried out for 30 minutes at 150V. Gels were first visualized by UV 
transillumination and fluor-imaging detection using a Chemi-Doc Imager (Bio-Rad, Hercules, 
CA). Gels were then fixed by rinsing in 70% ethanol for 30 min and stained overnight with 
Stains-All or dimethylmethylene blue (section 2.5) followed by destaining in 70% ethanol. 
Stained bands were imaged by trans-white light on the Chemi-Doc Imager. 
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2.5.  DMMB assay 
1,9-Dimethyl-Methylene Blue (DMMB) stock solution was prepared by dissolving 16 mg 
DMMB (Sigma-Aldrich, St. Louis, MO), 3.04 g Glycine, 2.37 g NaCl, and 95 ml 0.1 M HCl in 1 
L of water.   Chondroitin sulfate (CS; chondroitin-4-sulfate and chondroitin-6-sulfate from shark 
and whale cartilage, Sigma-Aldrich, St. Louis, MO) stock solution was prepared by dissolving 
CS in water to a concentration of 4 mg/ml by mixing overnight at 4oC.  The solution was then 
further diluted 80-fold to a working concentration of 50 µg/ml.  This working concentration of 
CS was then diluted to a series of concentrations ranging from 1 µg/20 µl down to 0 µg/20 µl to 
create a standard curve.  20 µl from each of the dilutions and samples were then added to a 96 
well microtiter plate (Corning Incorporated, Corning, NY) in triplicate, along with 180 µl of 
DMMB stock solution.  The absorbance was immediately read at 525 nm on a Multiskan Ascent 
plate reader (Thermo Scientific). 
 
3.  Cell culture 
3.1.  Rat chondrosarcoma cell culture 
The rat chondrosarcoma cell line (RCS) is a continuous long-term culture line derived 
from the Swarm rat chondrosarcoma tumor (37). The RCS cell line in the Knudson laboratories 
was a gift of Dr. James H. Kimura (formerly of Rush University Medical Center) and 
represented an early clone of cells that eventually became known as long-term culture RCS (38). 
RCS chondrocytes were cultured as high-density monolayers (2.0 x 10
6 cells/ cm
2
) in DMEM 
(Mediatech, Herndon, VA) containing 10% fetal bovine serum (FBS; Hyclone, South Logan, 
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UT) and 1% L-glutamine and 1% penicillin-streptomycin, and incubated at 37oC in a 5% CO2  
environment. The RCS cells were passaged at confluence using 0.25% trypsin/2.21 mM EDTA 
(Sigma). 
 
3.2.  Hyaluronidase treatment to remove pericellular matrix 
Cells were plated in monolayer for a minimum of 48 hours.  A solution of 200 U/ml of 
bovine testicular hyaluronidase (Sigma) or 5 U/ml Streptomyces hyaluronidase (Sigma) was 
prepared in media containing 10% FBS.  The bovine testicular hyaluronidase solution was added 
to the monolayer for 20 minutes at 37oC, while the Streptomyces hyaluronidase solution was 
added to the monolayer for 90 minutes 37oC.  Cells were rinsed in PBS after treatment.   
 
3.3.  Chloroquine efficacy assay 
A simple fluorescent microscopy experiment was performed to find the optimum dosage 
of chloroquine for RCS cells.   A stock solution of chloroquine (Sigma) was produced by 
dissolving chloroquine in media containing 10% FBS to a final concentration of 100 µM.  RCS 
cells were incubated in monolayer for 48 hours at 37oC.  Aliquots of the stock chloroquine 
solution were diluted with media containing 10% FBS to final concentrations between 100 µM 
to 3.125 µM.  These dilutions were then added to wells containing the RCS cells and allowed to 
incubate for 24 hours at 37oC.  To determine efficacy of the chloroquine aliquots, the cells were 
rinsed with media, then a solution of 1 µl of LysoTracker Red (Invitrogen) was mixed with 20 
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ml media and added to the wells.  The LysoTracker Red will stain positively for low pH vesicles, 
thus indicating an ineffective chloroquine dosage.  The confluency of the cells was also observed 
to determine cytotoxicity by chloroquine.  The optimum chloroquine concentration was chosen 
by observing which sample exhibited a lack of LysoTracker Red staining, while also maintaining 
cell confluency.   
 
4.  Particle exclusion assay 
 RCS chondrocytes were cultured overnight in 35-mm wells.  The medium was replaced 
with 700 µl of a suspension of formalin-fixed erythrocytes in PBS (31). Cells were photographed 
using a Nikon TE2000 inverted phase-contrast microscope and images were captured digitally in 
real time using a Retiga 2000R digital camera (QImaging, Surrey, British Columbia). The 
presence of cell-bound ECM is seen as the particle-excluded zone surrounding the chondrocytes. 
 
5.  Visualizing FITC-HA binding and internalization 
5.1.  Fluorescent microscopy 
 For immunofluorescence studies, RCS were plated into 4-well chamber slides (Thermo 
Fisher Scientific) at 12,000 cells/well and cultured for 24 h.  Prior to assay the cell monolayers 
were treated for 20 minutes at 37oC with 200 turbitity reducing units (TRU)/ml of bovine 
testicular hyaluronidase or 5 units/ml Streptomyces hyaluronidase prepared in media containing 
10% FBS.  The cells were then rinsed repeatedly and incubated with FITC-HA or FITC-
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HA/aggrecan aggregates, at varying concentrations, for 3 h at 4 oC to visualize total extracellular 
binding, or for 24 h at 37 oC to visualize internalized HA. After incubation, cells were rinsed 
with PBS and fixed directly (to visualize total binding) or post-treated with 5 units/ml 
Streptomyces hyaluronidase (to visualize internalized HA and aggrecan only) prior to fixation in 
4% paraformaldehyde for 10 minutes at room temperature. The fixed cells were quenched with 
0.2 M glycine in PBS and mounted using Fluoro-Gel medium containing DAPI nuclear stain 
(Electron Microscopy Sciences, Hatfield, PA). Accumulation of FITC-HA was visualized using 
a Nikon Eclipse E600 microscope equipped with Y-Fl Epi-fluorescence (Melville, NY), a 60x 
1.4 n.a. oil- immersion objective, and FITC (green) and DAPI (blue) filters. Images were 
captured digitally using a Retiga 2000R digital camera and processed using NIS Elements BR 
version 1.30 imaging software (Nikon, Lewisville, TX). 
 
5.2.  Flow cytometry 
RCS chondrocytes were incubated with FITC-HA or FITC-HA/aggrecan aggregates 
under similar conditions as the immunofluorescence studies. After hyaluronidase treatment, the 
cells were released into a single cell suspension using 0.25% trypsin (Mediatech, Manassas, 
VA).  The cells were then quantified using a FACScan
TM cytometer (Becton Dickinson, Palo 
Alto, CA) with CELL Quest software.  Log fluorescence channel versus cells per channel was 
plotted for 10,000 cells. 
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5.3.  BCA assay for protein concentration determination  
 A 2.0 mg/ml stock solution of bovine serum albumin (Thermo Scientific) is diluted to 
concentrations of 2.0 / 1.0 / 0/5 / 0.25 / 0.125 / 0.0625 / 0.03125 / 0.015625 / 0.0078125 / 0 
mg/ml.  To make a standard curve, 25 µl/well of these samples are then added in triplicate to a 
96 well polystyrene plate (Corning Incorporated).    Next, 25 µl of the protein lysate to be 
quantified is added to a well, followed by addition of 200 µl of BCA reagent (5.0 ml reagent A + 
100 µl reagent B; Thermo Scientific) to each well. The plate was incubated at 37oC for 30 
minutes before absorbance was read at 540 nm on a Multiskan Ascent plate reader (Thermo 
Scientific).  A linear graph is made from the standard curve, and the equation of the slope is used 
to calculate the protein concentration of the cell lysate.   
 
5.4.  Western blots 
Total protein was extracted using cell lysis buffer containing protease inhibitor (Sigma) 
and phosphatase inhibitor cocktails 2 and 3 (Sigma). Equivalent protein concentrations as 
determined by a BCA assay were loaded onto 4-12% NuPAGE Bis-Tris gels (Novex, Carlsbad, 
CA).  Following electrophoresis, proteins within the acrylamide gel were transferred to a 
nitrocellulose membrane (Bio-Rad Laboratories, Inc.) using a Criterion blotter apparatus (Bio-
Rad Laboratories, Inc.), and the nitrocellulose membrane was then blocked in 5% non-fat dry 
milk in Tris buffered saline containing 0.1% Tween 20 (TBS-T) for 1 hour. Anti-Flag M2 
antibody (Sigma) diluted 1:2,000 in TBS-t containing 5% milk was used to detect 3x-Flag tagged 
aggrecan globular G1 domain protein. Prior to use, the antibody was conjugated with HRP 
following the protocol for the Lightning-Link HRP conjugation kit (Innova Biosciences) to avoid 
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the use of secondary reagents. Detection was performed using SuperSignal West Pico 
chemiluminescence substrate (Thermo Scientific). 
 
5.5.  Morphometric analysis of fluorescence microscopy images 
Changes in mean pixel intensity of FITC-HA bound to or localized within RCS 
chondrocytes were quantified using NIS-Elements BR2.30 imaging software (Nikon).  Single 
region-of-interest (ROI) squares of equal size (area=55 µm2) were placed over each cell within a 
field-of-view to be quantified (Figure 7).  The ROI covered the majority of the cell cytoplasm of 
RCS cells when viewed through a 60x objective.  Three similarly sized squares were placed over 
cell-free areas within the field for determination of background intensities.  Mean pixel intensity, 
maximum pixel intensity, mean pixel density, mean pixel brightness, and sum pixel intensity 
were determined for each ROI represented on each 12 bit-grey scale cell image (0-4095 relative 
intensity values). Twenty-five cells were analyzed for each condition within an individual 
experiment.  Box plots were produced to display the results from a single experiment 
representing 25-30 cells.  Bar graphs were then produced by averaging multiple experiments and 
normalizing compared to the positive control (FITC-HA alone).  This was necessary to account 
for the variable fluorescein conjugation between different batches of FITC-HA.   
 
5.6.  Statistical analysis 
All data were obtained from at least three independent experiments performed in 
triplicate.  Statistical significance was determined using the two-tailed unpaired Student’s t test. 
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A p- value of less than 0.05 was considered significant. 
 
6.  Producing HA and proteoglycan of decreasing size 
6.1.  Sonication of HA 
To prepare shorter length HA, a FITC-HA sample was cooled in an ice bath and 
sonicated with a microtip probe at output level 6 for 15-60 seconds using a W-220 sonicator 
ultrasonic processor (Heat Systems-Ultrasonic, Plainview, NY) as described previously (128). 
 
6.2.  Clostripain digestion of aggrecan  
 Clostripain from Clostridium histolyticum was diluted to 5 units/ml (20 µg/ml) in 0.6 mM 
dithiothreitol, 5.0 mM CaCl and the enzyme activated by incubating at 37oC for 3 hours (42,43). 
Purified aggrecan (6.0 mg/ml) or HA/aggrecan aggregates (0.5-1.0 mg/ml), dissolved in 0.1 M 
Tris, 0.1 M NaC2H3O2 were mixed 1:1 (v/v) with the activated clostripain solution (42). At 
various times (5 to 60 minutes), the enzymatic activity was deactivated by addition of 
iodoacetamide to a final concentration of 1.1 mM. Digested proteoglycan-containing 
preparations were then precipitated by adjustment of the solution to 70% (70 ml/100 ml) ethanol 
containing 1.3% (1.3 g/100 ml) potassium acetate. 
 
 
	  	   44	  
7.  Co- immunoprecipitation of HYAL-2 with CD44 
C28/I2 chondrocytes, a kind gift from Dr. Mary Goldring (Hospital for Special Surgery, 
New York, NY), were grown in monolayer for 48 hours, washed with PBS twice, scraped, and 
then pelleted by centrifuging at 1,300 rpm for 10 minutes.  Cells were lysed on ice for 30 
minutes using a cocktail composed of 10x cell lysis buffer (Cell Signaling, Beverly, MA) diluted 
to 1x in water, 20 µg/ml Halt protease inhibitor cocktail (Thermo Scientific, Rockford, IL), and 
20 µg/ml of Phosphatase Inhibitor 2 and 3 (Sigma, St. Louis, MO).  Cell lysis solution was then 
centrifuged for 10 minutes at 13,000xg at 4oC.  A BCA assay (Thermo Scientific) was then 
performed on the resulting supernatant to obtain the total protein concentration.  500 µg of total 
protein was then allowed to mix at 4oC for two hours with 200 µl PBS (Amresco, Solon, OH) 
supplemented with 0.2% Tween-20 (Fisher Scientific, Fair Lawn, NJ) and 5 µl of anti-CD44 
cytotail antibody (Affinity Bioreagents) (129).  50 µl of Protein A/G PLUS-Agarose beads 
(Santa Cruz Biotechnology, Dallas, TX) were then added to the solution and allowed to mix for 
an additional two hours at 4oC to allow the CD44-antibody complex to bind to the protein A/G 
conjugated agarose beads along with any protein bound to CD44.  The beads were then washed 
three times by centrifuging at 2,500 rpm for 10 minutes at 4oC and resuspended in 100 mM 
phosphate buffer, 50 mM NaCl at pH 6.5.   This method is useful for not only enriching the 
HYAL-2 population, but also it will only precipitate HYAL-2 that is bound to CD44.  These 
HYAL2-CD44-beads were then used in an assay to detect hyaluronidase activity (see 8.1).  By 
western blot, we can see the CD44 and the HYAL-2 after this co-immunoprecipitation strategy 
(5).  
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8.  Detection of HA degradation 
 8.1.  Agarose gel electrophoresis 
Hyaluronidase activity was examined by visualizing the reduction in size of high 
molecular mass, FITC-HA on 1% agarose electrophoresis gels. FITC-HA was prepared as 
described previously (33).  For this assay, CD44-HYAL-2 complexes were prepared from lysates 
of confluent cultures of C28/I2 chondrocytes and immunoprecipitated as described above 
(section 7) using Magnetic Protein G Dynabeads®. Following overnight incubation at 4oC the 
beads/complexes were collected, the supernatant discarded and beads washed twice in 100 µl of 
200 µg/ml of FITC-HA in 50 mM NaCl, 100 mM phosphate buffer at pH 6.5 or pH 4.8.  The 
beads were then resuspended in 100 µl of 200 µg/ml of FITC-HA at pH 6.8 or pH 4.8 and 
allowed to incubate in a 37oC incubator with gentle rotational mixing. At 24-hour intervals, 15 µl 
aliquots were applied to a 1% agarose gel (IBI Scientific) in Tris acetate EDTA buffer (IBI 
Scientific) and electrophoresed for 30 minutes at 150 V.  Fluorescent bands were visualized and 
imaged using transillumination of a fluorimaging system (Chemi-Doc). The gels were then fixed 
and stained with 0.015% Stains-All in formamide buffer, destained in water and re-imaged. 
 
8.2.  Quantifying FITC-HA cleavage on agarose gels 
 The extent of FITC-HA band migration visualized on agarose gels due to enzymatic 
cleavage was quantified using Quantity One densitometry software for n = 3 experiments at pH 
6.8 and n = 2 experiments at pH 4.8.  Pixel intensities of the agarose gel lanes were derived from 
12-bit RAW images on a scale from 0-4096.  For each agarose gel (representing an individual 
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experiment), digital scans of sample lanes (of equal scan length) were prepared and assigned Rf 
values between 0 and 1.0.  A digital plot for each gel was produced depicting pixel intensities on 
the y-axis versus the Rf value on the x-axis.  The Rf value corresponding to the peak pixel 
intensity for each sample, and the control, were obtained.  The ratio of Rf values (sample : 
control) was calculated for each sample on each gel.  An unpaired Student’s t-test was used to 
evaluate the ratio for each sample compared to control and a p value <0.05 was considered 
significantly different from control. 
 
8.3.  Biotin-HA ELISA 
As an alternative means to measure hyaluronidase activity, an ELISA assay was adapted 
from previous investigators (130) where HA conjugated with biotin was adhered to the bottom of 
an ELISA plate and was allowed to be cleaved away by membrane fragments from bovine 
articular chondrocytes, containing HYAL-2 bound to CD44 (4).   A 96 well, medium-binding 
polystyrene ELISA plate (Corning Incorporated, Corning, NY) was prepared by incubating 100 
µl/well of serially diluted biotin-HA in 20 mM carbonate-bicarbonate coating buffer overnight at 
4oC.  Chondrocytes were isolated from young bovine metacarpophalangeal joint cartilage 
following extraction with 0.2% pronase (EMD Millipore Corp., Billerica, MA) and 0.025% 
collagenase (129).  The cells were incubated in monolayer for 48 hours in media containing 10% 
serum.  The cells were washed in PBS, scraped, and then sonicated in an ice bath with a microtip 
probe at output level 6 for 40 seconds using a W-220 sonicator ultrasonic processor (Heat 
Systems-Ultrasonic, Plainview, NY).  The fragmented membrane mixture was then centrifuged 
for 5 minutes at 400 X g to pellet intact cells.  The supernatant was then centrifuged at 20,000 X 
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g for 1 hour at 4oC to pellet the membrane fragments.  The resulting pellet was washed, and then 
resuspended in 50 mM NaCl, 100 mM phosphate buffer, pH 6.8.  The ELISA wells were washed 
three times in ELISA wash buffer (0.05% tween-20 in PBS), and then the fragmented membrane 
mixture was added to the wells and allowed to incubate for 3 hours at 37oC.  The membrane 
mixture was removed by washing the wells three times with ELISA wash buffer, followed by a 
20 minute incubation of a streptavidin-HRP (R&D Systems, Minneapolis, MN) diluted 1: 200 in 
ELISA dilution buffer (5% tween-20 in PBS).  Wells were washed 3 times in ELISA wash 
buffer, followed by an additional 20 minute incubation in ELISA substrate reagent (1:1 mixture 
of peroxide solution and chromogen solution; R&D Systems, Minneapolis, MN).  The reaction 
was stopped by the addition of 2N H2SO4.  Absorbance was read at 450 nm and 540 nm on a 
Multiskan Ascent plate reader (Thermo Scientific).  The absorbance at 450 nm was subtracted 
from the absorbance at 540 nm to eliminate the background 
	  	   48	  
 
 
	  	   49	  
Figure 7:  Morphometric analysis of fluorescent microscopy images 
Figure shows a representative image of the process of quantifying the fluorescence from 
fluorescent microscopy.  Once an image was acquired, the image was enhanced and false colored 
to make the fluorescence easier to measure using the NIS-Elements software.  Boxes of equal 
size were placed over every cell to include the majority of the cytoplasm.  Three additional boxes 
were placed in areas absent of cells to provide a blank reading.  The three blank readings were 
averaged together to obtain an accurate background fluorescence, which was subsequently 
subtracted from the other readings.  A chart was generated displaying various data points such as 
mean pixel intensity, maximum pixel intensity, mean pixel density, mean pixel brightness, and 
sum pixel intensity.  The mean pixel intensities were used to quantify and compare the amount of 
fluorescence (FITC-HA) in subsequent experiments. 
 
 
 
 
 
 
	  	  
CHAPTER 3:  RESULTS 
 
1.  The visualization of hyaluronan  
 In the past, visualizing HA and its size has been a labor intensive and costly procedure.  
Typical protocols included analysis of radioactively-labeled HA, separated by size exclusion 
chromatography, and detected by scintillation counting (109).  Recently, some investigators have 
used agarose gels of varying concentrations to detect the presence and size of HA through 
electrophoresis (131,132).  Through trial and error, agarose gels at a concentration of 1% were 
found to successfully produce a reasonable separation of high, middle, and low molecular weight 
HA detected by stain-all (Figure 8A) and fluorescein conjugated HA (FITC-HA) with UV 
transillumination (Figure 8B).  Agarose gels of a higher concentration inhibited band migration 
causing a reduction in band separation, while lower concentration agarose gels produced 
elongated, blurry bands (data not shown).  Additionally, using concentrations of HA above 
1mg/ml have been found to cause the HA to tangle, and thus inhibit migration from the loading 
well.  This technique was subsequently used to visualize purified cartilage matrix proteoglycan 
and its reconstitution with HA.   
 
2.  Isolation and visualization of proteoglycan from bovine articular cartilage 
 Aggrecan monomer is not always available as a commercially available product.  
However, when it is available, the purity and integrity of the aggrecan monomer is unknown.  
For quality assurance purposes, a better alternative is to isolate and purify intact aggrecan 
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monomer in the lab, thus avoiding supply and quality issues.  Several methods were investigated 
for their ability to purify intact, functional aggrecan in large amounts.  HA affinity column 
chromatography was first attempted, but due to the lengthy procedure to only purify a very small 
amount of proteoglycan, this method was not practical.  DEAE column chromatography was also 
investigated for its ability to purify proteoglycan.  This method also proved to be impractical due 
to its small PG yield, as well as its tendency to also isolate out the native cartilage HA.  This 
attribute of DEAE chromatography may be beneficial to future investigations examining native 
HA/aggrecan aggregates.  The most favorable method for purifying cartilage proteoglycan was 
found to be a dissociative CsCl density gradient ultracentrifugation.  This protocol allowed for 
large amounts of proteoglycan, free of contaminants, to be purified at once.  
 
2.1.  DEAE ion exchange chromatography 
 Diethylaminoethyl (DEAE) cellulose beads are considered a weak anion exchanger for 
use in ion exchange chromatography.  These positively charged resin beads are commonly used 
in chromatography columns to retain and isolate negatively charged proteins and nucleic acids.  
In articular cartilage, HA and extracellular proteoglycans are negatively charged and will be 
retained in a column containing these beads.  Articular cartilage was extracted from young 
bovine metacarpophalangeal joints and dissociated in 4 M guanidine HCl for 48 hours.  The 
resulting cartilage slurry was dialyzed against water to dilute the guanidine solution at least ten 
fold to return the solution to associative conditions.  The slurry was then dansylated and then 
mixed with the DEAE beads.  The beads exhibited no autofluorescence before addition of the 
dansylated cartilage slurry when visualized with a microscope to see phase contrast (Figure 9A) 
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and fluorescent (Figure 9B) images of the beads.  The column was then rinsed with 0.2 M NaCl 
to elute out the nonbinding portion of the cartilage slurry.  After the eluent reached equilibrium, a 
sample of the beads was once again visualized by fluorescent microscopy to visualize the 
dansylated material being retained by the column (Figure 9C + 9D).  To elute the retained, 
dansylated material, 50 ml of 4 M guanidine HCl was rinsed through the column.  The beads 
were once again visualized to confirm the disappearance of fluorescence upon dissociative 
elution (Figure 9E + 9F).   
 
The purified sample was dialyzed against water to return the sample to associative 
conditions.  The proteoglycan was visualized by running a sample on a 1% agarose gel (Figure 
10).  For reference purposes, three commercially available HA samples were run in duplicate.  
Since DEAE columns retain all negatively charged substances, both HA and aggrecan were 
isolated.  An additional way that HA could be retained by a DEAE column is by its association 
with aggrecan.  Under associative conditions, an aggrecan monomer could bind a DEAE bead by 
its sulfated glycosaminoglycans, and still bind an HA filament, thus retaining the HA.  Once the 
eluted materials were returned to associative conditions, the aggrecan would reconstitute to the 
HA, forming a high molecular mass HA/aggrecan aggregate that remains in the loading well due 
to its massive size (DEAE lane).  This type of purification method would be useful for 
investigators studying the size change of HA and proteoglycan in diseased tissue.  A main 
drawback, however, is that the amount of resulting proteoglycan is too small to be used in 
subsequent internalization studies.     
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2.2.  CsCl gradient ultracentrifugation 
 Aggrecan monomer was isolated from young bovine metacarpophalangeal joint cartilage 
following extraction of pulverized tissue with 4 M guanidine HCl.  The cartilage extract was 
centrifuged in a CsCl gradient under dissociative conditions to yield a D1 fraction containing 
proteoglycan monomer.  Equilibrium density centrifugation separates cartilage molecules based 
on density with proteoglycans and glycosaminoglycans being the densest macromolecules, 
readily separate from lipids, proteins, and nucleic acids.  Moreover, since the ultracentrifugation 
was performed under dissociative conditions, link protein was not co-purified with the 
proteoglycan.  The physical properties of this aggrecan preparation were analyzed by 
electrophoresis on 1% agarose gels.  The D1 fraction-aggrecan monomers ran as a unimodal but 
disperse band at the low end of the high molecular mass HA standard (Figure 11A).  No change 
in migration of the aggrecan monomer was observed following treatment with Streptomyces 
hyaluronidase suggesting no contamination by HA present in the neighboring D2 fraction of the 
CsCl gradient.   As a positive control, high molecular mass HA treated with Streptomyces 
hyaluronidase migrated to a region of small oligosaccharides within the gel (Figure 11A, lane 2).   
Aggrecan monomer exposed to exhaustive treatment with clostripain protease (CP) shifted to 
faster migrating bands indicative of degradation of the proteoglycan core protein (Figure 11A, 
lane 5 and 11B, lane 4).   Panel 11B was stained with DMMB indicative of sulfated 
glycosaminoglycans such as keratan sulfate and chondroitin sulfate; HA in lane 1 was not 
detected by DMMB.  
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 The traditional application of DMMB dye has never, to our knowledge, been used for 
staining of agarose gels, but rather as a colorimetric agent in a DMMB assay.  This 
spectrophotometric assay was originally developed to quantify the levels of sulfated 
glycosaminoglycans in biological samples (133-135).  This assay works by observing the shift in 
absorption when the DMMB dye binds to a negatively charged sulfate on a glycosaminoglycan 
chain.  This assay was used as an additional experiment to confirm that the purified material 
from the CsCl ultracentrifugation was proteoglycan.  A 50 µg/ml stock solution of chondroitin 
sulfate (CS) solution was serial diluted to produce a standard curve.  A serial dilution of 
equivalent concentrations of purified PG was also produced.  To perform the DMMB assay, 20 
µl of each sample was added to a 96 well plate in duplicate, followed by 180 µl of DMMB 
solution.  The absorbance was then immediately read at 540 nm.  The averages of the duplicate 
readings were then plotted on a graph to visualize the effect of CS concentration on the 
absorbance (Figure 12).  The D1 fraction, like the CS standard, increases in absorbance with 
increasing concentration.  This experiment illustrates that as the concentration of the CS standard 
increases the absorbance also proportionally increases, this is due to the presence of negatively 
charged sulfate groups.  The CsCl purified D1 fraction exhibits the same pattern, thus illustrating 
that the D1 fraction contains sulfated glycosaminoglycan, a characteristic of ECM proteoglycans 
like aggrecan. 
 
3.  Visualization of reconstituted HA/aggrecan aggregate 
To verify that the purified aggrecan monomer retained a functional capacity to bind to 
HA, the D1 aggrecan monomer was mixed in varying proportions with a fixed concentration of 
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FITC-HA and allowed to re-aggregate.    Figure 13A depicts Stains-All detection of FITC-HA 
and aggrecan monomers.   Upon re-aggregation, HA / aggrecan aggregates exhibited a size shift 
wherein all of the aggrecan visualized by DMMB staining (Figure 13B) was now detected in the 
loading wells of the agarose gel.   The same gel under UV transillumination, which detects the 
FITC-HA exclusively, showed a size shift of the HA which co-localized with aggrecan in the 
loading wells (Figure 13C).   It is important to note that a minimal ratio of aggrecan / FITC-HA 
of approximately 2:1 was required to consistently obtain a complete size shift of the FITC-HA 
(Figure 13C).  It should also be noted that a small percentage of the aggrecan monomer 
population does not exhibit a size shift in the presence of HA (Figure 13B). 
 
Another approach to verify the functionality of the D1 aggrecan fraction was to observe 
its ability to bind to endogenous HA on live cells in culture.   A particle exclusion assay was 
used to visualize the presence of pericellular matrices surrounding our model chondrocyte cell 
line, rat chondrosarcoma (RCS) cells.  Figure 13D depicts the small particle-excluding coats 
present on RCS cells after 48 h culture in monolayer.  As we have shown previously (136-138), 
these pericellular matrices are dependent on HA as a scaffold as pretreatment of the RCS cells 
with 5 U/ml Streptomyces hyaluronidase removed the coat allowing the particles to abut the 
plasma membrane (Figure 13F).  When fresh medium containing 2 mg/ml aggrecan monomer 
was added to the RCS cells for 1 hour, large particle-excluding coats, up to one-cell-diameter in 
size, were now observed (Figure 13E).    Post-treatment of cells (as in Figure 13E) with 
Streptomyces hyaluronidase resulted in a rapid depletion of the pericellular matrix (Figure 13G).   
These experiments demonstrate that the purified D1 aggrecan monomer is functionally 
competent to reconstitute with HA into an aggregate structure and contains sufficient 
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glycosaminoglycan substitution to support assembly of a robust, hydrated pericellular matrix 
typically associated with primary chondrocytes.     
 
4.  HA and HA/aggrecan aggregate equally bind cells 
The goal of this study was to determine the extent to which the binding of aggrecan to 
HA filaments affects HA endocytosis.   As such, it was first necessary to demonstrate that FITC-
HA, with or without bound aggrecan monomers, bound in an equivalent fashion to the plasma 
membrane / pericellular matrix of the RCS cells.  Hyaluronidase pre-treated cultures were 
incubated with medium containing FITC-HA alone or FITC-HA/aggrecan aggregates for either 3 
h at 4 oC (Figure 14A, C, E) or 24 h at 37 oC (Figure 14B, D, F).   From here onward, aggrecan 
will be designated simply as proteoglycan (PG), FITC-HA (HA) and FITC-HA/aggrecan 
aggregates as HA+PG.  Nearly equivalent fluorescence was observed between RCS cultures 
incubated with HA alone (Figure 14C, 14D) or HA+PG (Figure 14E, 14F).  Cultures held at 4 oC 
presumably depict HA or HA+PG retained exclusively at the cell surface with little 
internalization (Figure 14C, 14E).   Cultures incubated for 24h at 37 oC represent intracellular 
and extracellularly localized FITC-HA (Figure 14D, 14F). However, the majority of the 
punctate, clustered fluorescence observed in Figure 14D and 14F is extracellular and sensitive to 
trypsin or Streptomyces hyaluronidase as will be shown in Figure 18.  Fluorescence was 
quantified using Nis-elements software (Figure 7).  Mean pixel intensity of cells illustrated in 
Figure 14 was quantified with subtraction of background (Figures 14A, 14B) and included cells 
from other fields of view.   Box plots of the representative experiments shown, both at 4 oC 
(Figure 14G) and 37 oC (Figure 14H), demonstrate nearly equivalent binding of FITC-HA (-) 
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and HA+PG (+).  The bar graph of percent change of averaged mean pixel intensities of the 
HA+PG conditions, as compared to HA alone (value set to 100%), from 4 independent 
experiments performed at 4 oC (Figure 14I) again demonstrate that the differences between total 
binding of HA (-) and HA in the presence of PG (+) were not significant. 
 
5.  Effect of aggrecan on HA endocytosis by RCS cells 
5.1.  Chloroquine efficacy test 
RCS cells were treated with chloroquine to allow for the accumulation of internalized 
HA.  Without chloroquine, internalized HA would be fragmented and turned over in lysosomes 
by hyaluronidases.  Chloroquine inhibits proton pumps in endosomes, thus preventing the 
acidification of these intracellular vesicles.  Treating cells with too much chloroquine is 
cytotoxic, while too little will not effectively inhibit lysosomal acidification.  RCS cells were 
incubated overnight in media containing a serial dilution of chloroquine (3.125 µM – 100 µM).  
The cells were then stained with LysoTracker Red, which stains for low pH vesicles, indicative 
of lysosomes (Figure 15).  Cell confluence and negative staining for LysoTraker Red were 
observed to determine the optimum chloroquine dose for RCS cells.  From this experiment, 25 
µM was found to be effective at inhibiting acidification of lysosomes (negative LysoTracker Red 
staining), thus reducing lysosomal enzyme activity, with limited cytotoxicity to the RCS cell 
line.  This concentration of chloroquine will be used in all subsequent internalization studies. 
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5.2.  Western blot 
 To evaluate the ability to detect HA binding and endocytosis, a western blotting approach 
was used.  This method utilized serum free conditioned media from a human epithelial kidney 
cell line (HEK293) stably transfected with a plasmid that overexpresses the aggrecan G1 domain 
as a fusion protein with an epitope tag (FLAG).  FLAG-tagged aggrecan G1 is secreted from 
these cells and detectable by immunoblot of conditioned media from the HEK293 cells.  
Previous studies have shown that small aggrecan G1 domains (the domain of aggrecan that binds 
HA) can bind to HA and be co-internalized with the HA via CD44 (105,106).  As such, G1 
domains function as a useful probe for detecting / labeling HA on cells in culture.  RCS cells 
plated 250,000/well in a 12 well dish were incubated for 24 hours.  The cells were extensively 
washed, followed by the addition of media containing the flag tagged G1 domain +/- intact 
aggrecan in the presence of 25 µM chloroquine.  To detect G1 domain bound to extracellular 
HA, the cells were incubated for 1 hour at 4oC and then lysed (Figure 16, Total).  To visualize 
internalized G1 domain, the cells were incubated for 24 hours at 37oC and then trypsinized prior 
to lysis (Figure 16, Internalized).  The cell lysates were run on a PAGE gel, then transferred to a 
nitrocellulose membrane for western blotting.  The FLAG-tagged G1 domain was visualized on 
the membrane by incubation with a monoclonal anti-FLAG M2 primary antibody conjugated 
with HRP. The bands were detected using a chemiluminescent substrate.   
 
As detected using anti-FLAG M2 antibody, the band representing total bound FLAG 
tagged G1 domain was readily apparent (Figure 16, Total, G1), as a 67 kD protein and seemingly 
of equal size and density to the sample treated with flag tagged G1 conditioned media containing 
	  	   59	  
intact PG (Figure 16, Total, G1+PG).  The presence of aggrecan in the conditioned media does 
not appear to inhibit the aggrecan G1 domain from binding to HA (Figure 16, Total).  As shown 
in the particle exclusion assay (Figure 13D-G), a 1 hour incubation was adequate to allow 
aggrecan and G1 binding to endogenous HA.  Internalized aggrecan G1 domain was also 
detected in cell lysates after a 24 hour, 37oC incubation (Figure 16, Internalized).  The cells were 
trypsinized before lysis to eliminate cell associated HA.  The cells incubated with FLAG-tagged 
G1 conditioned media exhibit a faint band at 67 kD (Figure 16, Internalized, G1) versus no 
visible band for the cells treated with FLAG-tagged G1 conditioned media containing intact 
aggrecan monomer (Figure 16, Internalized, G1+PG).  This experiment was effective for 
showing equal binding to RCS cells between G1 and G1+PG samples, but the amount of G1 
internalized appears to be too small for a quantitative western blotting analysis.  A new or 
optimized approach needed to be developed that would be more sensitive to small changes of 
HA internalization such as flow cytometry or fluorescent microscopy. 
 
5.3.  Flow cytometry 
 Flow cytometry was another approach evaluated to visualize and quantify the amount of 
FITC-HA that had been internalized by RCS cells.  400,000 RCS cells were cultured in a 12 well 
plate for 24 hours.  Cells were then treated with 200 units/ml of bovine testicular hyaluronidase 
for 20 minutes.  After extensive rinsing, the cells were then incubated with FITC-HA with or 
without bound aggrecan in media containing 25 µM chloroquine.  After 24 hours, the cells were 
extensively rinsed, then trypsinized for 5 minutes to cleave the pericellular matrix and free the 
cells from the substratum.  The cells were then rinsed and centrifuged twice, then loaded into 
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5ml polystyrene tubes.  The amount of internalized HA was then characterized by using a flow 
cytometer to directly detect the fluorescein that was conjugated to the HA.  The mean channel 
fluorescence for 10,000 cells was obtained for each sample and presented in a histogram (Figure 
17A).  The mean channel fluorescence was also calculated and displayed in the histogram for 
undecorated FITC-HA (Figure 17A, red line) and FITC-HA + PG (Figure 17A, blue line).   In 
the example shown, flow cytometry was unable to differentiate between the two samples, as the 
mean channel fluorescence readings were almost the same.  This may suggest that the amount of 
FITC-HA being internalized is too small for the flow cytometer to accurately detect. On the other 
hand, when the same cells were visualized under a fluorescent microscope to visualize the 
internalized FITC-HA+PG (Figure 17B) and undecorated FITC-HA (Figure 17C), a noticeable 
difference was observed between the two samples, possibly illustrating a credible way to observe 
HA internalization.  In other experiments, differences in the mean channel fluorescence 
paralleled the patterns observed microscopically.  This variability of detection of differences in 
the intracellular internalized pool of FITC-HA led us to conclude that the fluorescence was near 
the limit of detection of flow cytometry, precluding its use in obtaining reliable quantitative 
differences between samples.  
 
5.4.  Fluorescent microscopy 
To more reliably visualize the internalized pool of FITC-HA, RCS cells were post-treated 
with either Streptomyces hyaluronidase or trypsin after incubations with HA or HA+PG for 24 
hours at 37 oC in the presence of 25 µM chloroquine.  Both of these hyaluronidase treatments 
removed extracellularly-exposed HA and HA+PG.  As shown in Figure 18C and 18D, FITC-HA 
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added alone was observed primarily within intracellular, perinuclear organelles as we have 
shown previously in rat, bovine and human chondrocytes as well as pCD44-transfected COS7 
cells (105,106,109,139,140).  Thus, the fluorescence observed in Figure 18 (and Figures 20-22) 
represent accumulated ligand internalized over the incubation period.  When RCS cells were 
incubated with HA+PG, green fluorescent vesicles were observed but the fluorescence intensity 
was substantially reduced (Figure 18E and 18F).   The difference between endocytosis of HA 
alone (-) and HA+PG (+) was verified by quantification of mean pixel intensities following post-
treatment with Streptomyces hyaluronidase (Figure 18G, 18I) and trypsin (Figure 18H).  Trypsin 
post-treatment generated more uniform rounded cells but ones that were released into suspension 
and more difficult to image in a single plane of focus.  Cells remained attached to the substratum 
following post-treatment with Streptomyces hyaluronidase and this condition was used for all 
subsequent experiments.   
 
6.  Limited C-terminal cleavage of aggrecan with clostripain protease 
Purified aggrecan was incubated with clostripain protease under conditions optimized to 
affect a limited digestion of the proteoglycan within a workable time period.   First, aggrecan 
was incubated with clostripain as a free monomer (Figure 19A).  A modest shift in migration on 
agarose gels was observed for aggrecan monomers exposed to clostripain with increasing 
incubation time at 37 oC (Figure 19A).  When these fractions were ethanol precipitated and re-
dissolved in the presence of HA to allow for re-aggregation, fractions at all time points still 
exhibited a shift in migration into the loading wells (Figure 19B).   An increase in non-shifted, 
DMMB-positive proteoglycan was also observed.   Next, when aggrecan was exposed to 
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clostripain as an HA+PG aggregate (Figure 19C), DMMB-positive proteoglycan remained in the 
loading wells of each time point.  As in the digestion of monomers (Figure 19B), a time-
dependent increase of faster migrating proteoglycan was also observed.  Each time point of the 
clostripain-digested HA+PG fractions was subsequently post-treated with Streptomyces 
hyaluronidase to release the PG within aggregates back to PG monomers.  Like clostripain-
digested monomers (Figure 19A) a modest shift in proteoglycan monomer size was observed 
(Figure 19D).   These results suggest that the clostripain conditions used provided for limited 
cleavage of aggrecan.  Given that similar results were obtained when using monomer or 
aggregate as substrate, N-terminal protection of aggrecan (protection afforded by digestion of the 
HA+PG aggregate) was not of major concern.   The results observed are consistent with 
clostripain cleavage that was predominately C-terminal.    Since the aggrecan monomer was 
more readily dissolved following post-clostripain ethanol precipitation / purification, the 
remaining experiments utilized clostripain-treated monomers. 
 
7.  Effect of limited C-terminal cleavage of aggrecan on HA endocytosis 
Aggrecan monomers were treated with clostripain protease for 0-60 minutes, precipitated 
and then reconstituted with FITC-HA into HA+PG.  The migration of FITC-HA on agarose gels 
shifted into the loading wells when re-combined with the 0 and 10 minutes treated monomers but 
displayed little movement when incubated with aggrecan treated for longer time points of 40 and 
60 minutes (Figure 20A).  Robust endocytosis of HA was observed with RCS cells incubated 
with HA alone (Figure 20B).  The level of internalization was substantially reduced when cells 
were incubated with HA+ intact PG (Figure 20C).  With only 10 minutes of clostripain treatment 
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of the aggrecan monomer, the HA+PG aggregate resulted in more RCS cells with green 
fluorescence-positive vesicles (Figure 20D); a significant increase over HA + intact PG 
conditions observed in Figure 20H.  Cells incubated with HA+PG aggregates with 40 or 60 
minutes clostripain exposure exhibited substantially higher FITC-HA endocytosis levels (Figure 
20F and 20G) with some of the high-end outlier cells (closed circles, Figure 20H) within the 
same mean pixel intensity range as cells incubated with FITC-HA alone.   These results suggest 
limited C-terminal cleavage of PG monomers proportionately removes the aggrecan-mediated 
impediment to HA internalization.   
             
            Additional experiments were performed to narrow the time range in which clostripain 
cleavage of aggrecan affects HA endocytosis.   Figure 20I depicts RCS cells incubated with HA 
alone; Figure 20J shows cells incubated with HA+ intact PG.   In this series, 5 and 10 minutes of 
clostripain exposure (Figure 20K, 20L) resulted in a small but nonetheless significant increase in 
FITC-HA + PG endocytosis (quantified in Figure 20Q).  However, 15 minutes of clostripain 
exposure (Figure 20N) resulted in a larger jump in FITC-HA + PG endocytosis nearly equivalent 
to HA alone (Figure 20Q).  Robust HA + PG endocytosis was also observed using aggrecan 
exposed for 20 and 30 minutes to clostripain (Figure 20O, 20P).   When mean pixel intensity 
from independent experiments were summarized (normalized to equivalent FITC-HA alone 
conditions; Figure 20R) the cut-off in aggrecan impedance of HA endocytosis occurred between 
10 and 15 minutes of clostripain treatment.   Nonetheless, even 5 and 10 minutes of clostripain 
cleavage allowed for significantly increased HA endocytosis as compared to intact aggrecan 
(Figure 20R).    Reducing the clostripain digestion time to between 0-10 minutes (Figure 20S) in 
another set of 2 independent experiments confirmed that even limited aggrecan cleavage (Figure 
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20S inset) had an impact on promoting HA endocytosis.  Although the clostripain time points of 
0-10 minutes are clearly significantly reduced in internalization as compared to HA alone 
(Figure 20S, asterisks), the 2-10 minute time points were each significantly higher in mean pixel 
intensity than HA+ intact PG.  This suggests that only minor processing of aggrecan can begin to 
release the HA endocytosis block. 
 
8.  Effect of HA size on HA endocytosis 
            Another means to reduce the size of HA+PG aggregates is to alter the size of HA.  Time-
dependent sonication at 4 oC was used to selectively reduce HA size of a particular FITC-HA 
preparation without changing the concentration or fluorescein conjugation specific activity.  
Sonication for 5-30 seconds generated a roughly proportional series of HA species of reduced 
length (Figure 21I).  Using the endocytosis of intact FITC-HA as the positive control (Figure 
21B), 5 second sonication of the FITC-HA preparation resulted in little comparative change in 
HA endocytosis (Figure 21C; quantified in Figure 21J, 21K).  However, after 10 seconds of 
sonication, a clear discernable increase in HA endocytosis was observed (Figure 21D), with 
incremental increases proportional to sonication time until reaching a maximum at 25 seconds.   
Several cells incubated with sonicated HA accumulated intense intracellular deposits of ligand 
such that these cells were designated as high outliers and not included in the calculation of mean 
pixel intensities (Figure 21J).  Analysis of four independent experiments is shown in Figure 21K 
as percent of positive control (HA with no sonication). 
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            In a second series of experiments, varying-time preparations of sonicated FITC-HA were 
combined with intact aggrecan monomer.  The combination with aggrecan size shifted the intact 
FITC-HA as well as FITC-HA sonicated for 5, 10 and 15 seconds into the loading wells of 
agarose gels (Figure 21T); no shifting was observed with longer sonication time preparations.   
When intact HA + intact PG was incubated with RCS cells, little internalization of HA was 
observed (Figure 21M).   Little increase in internalized HA was observed in 5 second or 10 
second sonicated HA + intact aggrecan (Figure 21N, 21O).   However, with sonication times of 
15 seconds or more, a clear and progressive increase in FITC-HA + intact aggrecan endocytosis 
was observed (Figure 21P-21S).   A box plot illustrates this significant change that occurred at 
15 seconds of sonication (Figure 21U); an event that is consistently observed upon repetition 
(Figure 21V).   It is possible that the 20, 25 and 30 seconds sonicated FITC-HA fractions are too 
short in HA length to retain an aggrecan monomer, consistent with the lack of size-shifting 
migration as shown in Figure 21T.  However, both the 10 second and 15 second sonicated HA + 
PG mixtures formed aggregates (Figure 21T).  The abrupt change in HA endocytosis between 
these two fractions (Figure 21O and 21P) suggests that only a limited number of proteoglycans 
bound to HA is necessary to impede HA endocytosis.   However, it is unclear whether the 
increase in HA endocytosis observed in the 15 second sonicated HA + intact PG experiment 
(Figure 21P) represents internalization of non-decorated FITC-HA or the co-internalization of an 
intact aggrecan.    
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9.  Effect of C-terminal cleavage of aggrecan on aggrecan endocytosis 
The data shown in Figure 20 demonstrated that after extended clostripain cleavage of 
aggrecan, HA+PG endocytosis is increased to levels only slightly less than endocytosis of HA 
alone.  However, these results are dependent on following the labeled HA.   To determine 
whether the clostripain-cleaved aggrecan in the HA+PG aggregate were co-internalized, the 
aggrecan core protein was labeled with dansyl chloride as the fluorescent marker.   As shown in 
Figure 22B, the addition of HA + intact dansyl-PG aggregates to RCS cells resulted in no 
endocytosis of the PG.   However, when cells were incubated with HA + dansyl-PG treated with 
clostripain for 30 minutes (conditions that mimic the experiment shown in Figure 20P), 
intracellular blue fluorescent vesicles were readily apparent; results of 2 independent 
experiments are shown in Figure 22D and 22E.   Thus the increase in HA endocytosis observed 
in Figure 20P is not due to the internalization of free HA following release of PG from the HA 
strand.  Even after 30 minutes of clostripain cleavage (Figure 22F) the smaller aggrecan 
monomer remained bound to HA and was co-internalized.  Similarly, when intact dansyl-PG was 
allowed to re-aggregate with 15 second sonicated HA and added to RCS cells, a dim but 
detectable intracellular blue fluorescence was observed (Figure 22C).    Upon quantification, a 
statistically significant higher level of cell-localized blue fluorescence pixel intensity, above that 
of the blank control or full-length FITC-HA + intact PG, was observed (Figure 22H, 22I).   We 
propose that this shortened length of 15 second sonicated HA contains fewer aggrecan 
monomers, perhaps as few as one intact proteoglycan per HA chain.  As such, the level of overall 
fluorescence intensity would be greatly reduced.  However, we cannot rule out that this limited 
HA-bound aggrecan could also have been proteolytically processed by endogenous 
endoproteinases during the incubation period.     
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10.  The participation of neutral pH hyaluronidase activity in chondrocytes 
10.1.  Detection of hyaluronidase activity using agarose gel electrophoresis  
In order to consider the possibility that HA is degraded enzymatically within the 
extracellular environment of cartilage, a critical evaluation of known hyaluronidase enzymes is 
required.  All hyaluronidases known to be present in chondrocytes (HYAL-1, HYAL-2, and 
HYAL-3) are low pH lysosomal hydrolases, theoretically inactive at neutral or near-neutral pH.  
However, a previous study found that transfected cells expressing high levels of CD44 and 
HYAL-2 exhibit near neutral pH hyaluronidase activity, while cells expressing HYAL-2 alone, 
in the absence of CD44, do not (3).  In other words, the HYAL-2 isoform uniquely exhibited 
activity at higher pH when it was presumably interacting with CD44.  A previous fellow in the 
Knudson laboratory determined that HYAL-2 isolated from chondrocytes exhibited 
hyaluronidase activity but activity that could only be detected at pH 3.7 (5).  However, the fellow 
also determined that a proportion of the HYAL-2 in native, living chondrocytes, interacts with 
the extracellular domain of CD44 at the plasma membrane (5).  Discovery of this interaction 
opened the possibility that HYAL-2, while bound to CD44 on chondrocytes, could be active in 
the near neutral pH extracellular environment.   
 
To study this, a more-sensitive hyaluronidase assay was developed based on visualizing 
changes in FITC-HA size by their migration on 1% agarose gels as shown in Figure 7.  Assays 
were developed that allowed chondrocyte HYAL-2 to maintain its interaction with CD44, while 
also being able to visualize the resultant FITC-HA cleavage at various pH levels.  Observing 
FITC-HA degradation in media incubated in non-transfected chondrocytes, by visualization on a 
	  	   68	  
1% agarose gel, was one method used to perform this.  Culture media containing high molecular 
mass FITC-HA was incubated on a confluent culture of C28/I2 chondrocytes (an immortalized 
human chondrocyte cell line) and allowed to incubate for 4 days.  No observable reduction in 
FITC-HA size occurred on an agarose gel between four separate assays when compared to the 
control (Figure 23A).  Subsequent densitometry quantification of the agarose gel using Quantity 
One software to measure migration of pixel intensity yielded similar results (Figure 23B and 
23C).  To increase the possibility of observing near neutral pH HYAL-2 activity, CD44/HYAL-2 
complexes were co-immunoprecipitated from lysed C28/I2 cells as a way to enrich the 
population of enzyme/receptor complexes.  Previous studies used this same method to 
demonstrate CD44 interaction with HYAL-2 on chondrocytes (5).  For the hyaluronidase assay, 
FITC-HA was added directly to the CD44/HYAL-2 complexes, still bound to the magnetic resin 
beads and then incubated at 37oC at pH 6.8 [near-neutral pH as defined by Harada and Takahashi 
(3)] for varying time points (Figure 24A, lanes 3).  No change in FITC-HA size was observed 
after the initial 24 hour incubation when visualized on a 1% agarose gel as compared to FITC-
HA mixed with control magnetic resin beads (Figure 24A, lanes 2) and blank FITC-HA alone 
(incubated at the same time and temperature but without exposure to magnetic beads, Figure 
24A, lanes 1).  Starting at the 48 hour time point, a slight reduction in the size of FITC-HA 
incubated with CD44/HYAL-2 containing beads was visualized when compared against the two 
controls.  This shift in size became more apparent with increasing incubation times of 72 and 96 
hours.  The small changes observed in the two controls represent non-enzymatic alterations of 
FITC-HA size, perhaps due to temperature, magnetic iron-induced free radical activity, or 
possible bacterial contamination.  As such, the more prominent reduction in FITC-HA size in the 
presence of CD44/HYAL-2 containing beads illustrates the potential for a weak enzymatic 
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activity at near neutral pH when the HYAL-2 is bound to CD44.  The migration of the FITC-HA 
bands on the agarose gels was quantified using Quantity One software.  The pixel intensities for 
samples incubated at 24 hours (Figure 24B), 48 hours (Figure 24C), 72 hours (Figure 24D), and 
96 hours (Figure 24E) are displayed as a chromatograph.  The migration of a sample (from the 
blank) was determined by the sum of all pixel intensities present within the Rf value range ≥ the 
Rf value of the blank at half height of the blank sample’s peak.  The normalized sum for a 
sample within this Rf value range was depicted as a percent of the sum of the blank sample 
pixels within this same range (Figure 24F).  While no reduction in size of FITC-HA can be 
observed on the 24 hour incubation on the agarose gel (Figure 24A, lane 3), there does appear to 
be a small increase in HA fragmentation when visualized on the normalized bar graph (Figure 
24E).  A more noticeable increase in HA fragmentation can be seen in the 72 and 96 hour time 
points (Figure 24E).   
 
It is possible that 6.8 is not the optimum pH range for HYAL-2 when bound to CD44, 
and that could explain the low enzymatic activity.  A previous investigator has found that a pH 
range between 4.5 and 5.5 was optimal for CD44/HYAL-2 enzymatic activity (4).  To identify if 
this pH range is indeed the preferred condition for CD44/HYAL-2, the experimental design from 
Figure 24 was repeated but at a pH of 4.8.  As shown in Figure 25A, in samples of FITC-HA 
incubated with CD44/HYAL-2 containing beads, a reduction in FITC-HA size was apparent 
even after 24 hours at pH 4.8.  When quantified using Quantity One software and visualized on a 
bar graph, a larger increase in FITC-HA fragmentation is detectable, compared to the previous 
experiment at pH 6.8, after a 24 hour incubation (Figure 25E).  This suggests that while 
CD44/HYAL-2 complexes can exhibit enzymatic activity at a near neutral pH, the enzyme is 
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more active at lower, more acidic pH ranges.  Given that pH 3.7 is the optimum for HYAL-2 as 
an independent hydrolase, the data also emphasize that the binding of HYAL-2 to CD44 results 
in a significant alteration in where HYAL-2 can function in cells. 
 
10.2.  Detection of hyaluronidase activity using ELISA  
 An additional method to detect hyaluronidase activity was investigated using a modified 
HA-ELISA.  In this assay, high molecular weight HA was first conjugated with biotin and then 
applied to ELISA plates.  This assay was similar to one developed by Harada and Takahashi (3).  
Non-solubilized membranes were prepared from sonicated chondrocytes.  Bovine articular 
chondrocytes were incubated in monolayer for 48 hours to grow to confluence then washed, 
scraped, and then sonicated for 40 seconds.  Differential centrifugation was used to prepare 
chondrocyte membrane fragments.  The rationale for this approach was to maintain native 
CD44/HYAL-2 interactions in the non-solubilized membrane fragments.  Equivalent protein 
levels of the chondrocyte membrane mixture were added to the biotin-HA-coated wells and 
allowed to incubate at pH 6.8.  If hyaluronidase activity exists under these conditions, it should 
cleave the biotin-HA from the ELISA plate, causing it to be washed away upon completion of 
the incubation period.  Any reduction in adhered biotin-HA will then be read on a microplate 
reader and compared against an untreated, control set of wells.  Control wells were also prepared 
by adding phosphate buffer pH 6.8 without membrane fraction to an identical series of wells.  
The ELISA plate was incubated for 3 hours at 37oC, washed, and then incubated with 
streptavidin-HRP followed by the substrate solution.  
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 The bar graph depicted in Figure 26 is representative of one such ELISA.  The red bars 
represent the control sample of the serial dilution of biotin-HA that represents the absorbance for 
a given amount of biotin-HA in each well.  This was performed to compare any reduction in 
biotin-HA retained in the wells following incubation with chondrocyte membrane fragments 
(Figure 26, blue bars).  Hyaluronidase activity would release the biotin-HA from the wells.  
Additionally, by having a series of biotin-HA of decreasing concentrations, it is more likely that 
enzymatic activity, however small, will be visualized more clearly by having less substrate 
(biotin-HA) present in the well.  As the amount of biotin-HA in each well decreases, the amount 
of biotin-HA lost from the well due to the chondrocyte membrane fragments is more noticeable.  
While this experiment illustrates a reduction in HA coating the ELISA well, likely due to 
hyaluronidase activity at pH 6.8, there are concerns with the validity of the results.  The most 
difficult problem associated with this assay was that the fragmented chondrocyte membranes had 
a tendency to coat the bottom of the ELISA plate during the 3 hour incubation, thus interfering 
with the absorbance reading.  Additionally, the washing required to successfully remove the 
membranes from the plate likely caused non-specific loss of the biotin-HA.  Secondly, the 
increased incubation times at 37oC resulted in a noticeable non-specific loss of biotin-HA from 
the ELISA wells.  Thus, while this experimental approach showed promise, it contained too 
many technical flaws that prevented us from obtaining reproducible and conclusive results.  
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Figure 8.  The visualization of HA 
Three commercially available HA standards were analyzed by electrophoresis on 1% agarose 
gels at a concentration of 1 mg/ml and detected with Stains-All reagent (panel A, shown in grey 
scale).  High denotes HA of 1,200 – 1,800 kDa; mid, HA of 180 – 350 kDa and; low, HA of < 5 
kDa.  The same HA samples were conjugated with FITC, and following electrophoresis were 
visualized with transillumination UV fluorescence (UV fluor, panel B). A 1 Kb DNA ladder 
standard (S) was used for reference and alignment of the gel, critical bands are labeled in panel 
A. 
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Figure 9.  DEAE chromatography column 
Dansylated cartilage matrix slurry was allowed to mix with DEAE beads under associative 
conditions to allow for retention of negatively charged ECM components.  Samples of the DEAE 
beads were visualized under a microscope at 40x magnification to visualize the beads with phase 
contrast (panels A, C, and E) and fluorescence in the UV spectrum (panels B, D, and F).  Prior to 
the addition of the dansylated cartilage mixture, the DEAE beads exhibited no background 
fluorescence (panel A and B).  Once the slurry was allowed to mix with the beads, and non-
binding components were rinsed away, the beads exhibited a blue fluorescence as a result of 
retained dansylated material (panel C and D). The column was washed with 4 M guanidine HCl 
to elute away the retained material.  After 50 ml of eluting, the beads completely lost their blue 
fluorescence (panel E and F).  The bars represent 20 µm, images in grey scale.   
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Figure 10.  Visualizing purified DEAE product 
Three commercially available HA standards were analyzed in duplicate against the DEAE 
purified material in associative conditions by electrophoresis on a 1% agarose gel and detected 
with Stains-All.  The eluted DEAE material contains HA decorated with aggrecan resulting in a 
large molecular mass aggregate that remains in the loading well upon electrophoresis (DEAE 
lane).  A DNA ladder was included for reference; images in grey scale. 
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Figure 11.  Analysis of purified aggrecan monomers   
Aggrecan was purified from cartilage slices derived from bovine metacarpophalangeal joints.  
Aliquots of the purified aggrecan D1 fraction (panel A, lanes 3-5; panel B, lanes 2-4) and high 
molecular mass HA (panels A and B, lane 1) were electrophoresed on 1% agarose gels and 
detected using Stains-All (panel A) or DMMB (panel B).  Some samples were pre-digested with 
Streptomyces hyaluronidase (panel A, lanes 2, 4; and B, lane 3) or clostripain protease (panel A, 
lane 5; panel B, lane 4) prior to electrophoresis.  A 1 Kb DNA ladder standard (S) was used for 
reference and alignment of the gel.  The data shown is a representative example of 4 replicated, 
independent experiments. 
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Figure 12.  DMMB assay 
Standard curves for chondroitin sulfate and CsCl purified aggrecan sample with 
dimethylmethylene blue (DMMB).  The CS standard was a commercially available whale and 
shark chondroitin-4-sulfate and chondroitin-6-sulfate (blue diamonds) and the D1 fraction was 
from the CsCl ultracentrifugation of bovine articular cartilage (red squares).  The samples (0-50 
µg/ml) were added in a 20 µl volume to 180 µl DMMB color reagent, and A540 was determined 
immediately after mixing.  The results shown are that of a single experiment performed in 
duplicate from a series of four experiments.       
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Figure 13.  Visualization of HA and reconstituted aggregate   
The ability of the purified aggrecan (D1 fraction) to form stable aggregates with HA was 
analyzed by observing size changes on 1% agarose gels following electrophoresis under non-
dissociative conditions.  Undecorated FITC-HA (HA) and various concentrations of aggrecan 
monomer (0.2 – 4.0 mg/ml) were first visualized with Stains-All (panel A).  Reconstituted 
aggregates were then established using a fixed concentration (500 µg/ml) of high molecular mass 
FITC-HA, combined with varying concentrations of aggrecan monomers (0.2 - 4.0 mg/ml) prior 
to electrophoresis on 1% agarose gels.  Band locations were then visualized by DMMB staining 
(panel B), or by transilluminator UV fluorescence (panel C).   Next, a particle exclusion assay 
was used to visualize the pericellular matrix that surrounds live cells.  Panel D: Control rat 
chondrosarcoma (RCS) cells with no treatment; Panel E, RCS cells after the addition of 2.0 
mg/ml aggrecan; Panel F: RCS cells pre-treated with Streptomyces hyaluronidase prior to the 
addition of aggrecan and; Panel G: RCS cells as in panel E post-treated with Streptomyces 
hyaluronidase.   High power images of individual cells are shown as insets.  The data shown in 
Panels D – G are a representative example of 5 replicated, independent experiments.   The bar in 
panel F is 20 µm and applicable to panels D-G. 
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Figure 14.  Binding of total HA and HA/aggrecan aggregate to cells   
RCS cells grown in chamber slides were treated with 200 TRU/ml bovine testicular 
hyaluronidase, washed extensively and then incubated for 3 h at 4oC (panels A, C and E) or 24 h 
at 37 oC (panels B, D and F) in control medium (Blank; panels A and B); medium containing 
FITC-HA alone (HA; panels C and D) or; aggregates of FITC-HA + aggrecan (HA+PG; panels 
E and F).  The washed cells were then fixed, mounted in medium containing DAPI nuclear stain, 
and visualized by fluorescence microscopy.  Shown are representative digital overlay images of 
green (HA) and blue (nucleus) fluorescence channels.  Images shown are representative 
experiments from 6 independent experiments performed at 4 oC; 3 independent experiments 
performed at 37 oC.  All bars are 20 µm.   Mean pixel intensity of 25-30 cells per each 
experimental condition were evaluated for experiments performed at 4 oC (panel G) and 37 oC 
(panel H).  Shown are the box plots of mean pixel intensities in RCS cells treated with FITC-HA 
without (-) or with (+) the inclusion of purified aggrecan.  Mean pixel intensities of cells 
recorded as outliers are included and shown as dark round circles (•).  The bar graph in Panel I 
represents the mean pixel intensity average ± SD of 6 independent experiments performed at 4 
oC and is illustrated as the normalized percent change in mean pixel intensity of HA+PG treated 
cells (+) as compared to RCS cells treated with HA alone (-) set to 100%.   
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Figure 15:  Chloroquine optimization assay 
 
A serial dilution of chloroquine was produced to ascertain the most effective concentration while 
minimizing cytotoxicity. Chloroquine (3.125 µM – 100 µM), prepared in media, was added to 
RCS cells that had been allowed to grow to confluence in monolayer.  After a 24 hour incubation 
with the chloroquine solutions, the cells were incubated with LysoTracker Red, to detect low pH 
vesicles.  A control well was performed to visualize the amount of LysoTracker Red staining 
untreated RCS cells exhibit.  The 25 µM concentration of chloroquine was chosen for use in all 
subsequent experiments due to its ability to prevent LysoTracker Red staining (thus preventing 
the acidification of lysosomes) and also maintaining a confluent cell culture.  Bars represent 20 
µm.   
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Figure 16:  Visualizing HA binding and internalization with western blot 
 High density monolayers of RCS cells were incubated in conditioned media containing 
flag tagged aggrecan G1 domain (G1) or conditioned media containing flag tagged G1 domain 
and intact aggrecan monomer (G1+PG).  To visualize total bound G1, RCS cells were incubated 
for 1 hour at 4oC, then detergent extracted (Total).  To visualize internalized G1, cells were 
incubated for 24 hours at 37oC, followed by trypsinization and then detergent extracted 
(Internalized).  As a control, one sample was incubated with media alone.  Equivalent amounts of 
each sample were processed for western blot analysis with immunoblotting performed using 
monoclonal anti-FLAG M2 primary antibody conjugated with HRP.  Bands are at 67 kD. 
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Figure 17:  Analysis of FITC-HA internalization by flow cytometry 
Flow cytometric analysis was used to compare the differences in the amount of internalized 
FITC-HA (panel A, red line) and FITC-HA + aggrecan (panel A, blue line).  Fluorescence from 
10,000 cells was read and quantified using a FACScan cytometer; the mean channel fluorescence 
for each sample is shown.  The black line represents a blank sample, RCS cells incubated in 
media containing no FITC-HA.  The same cells where then visualized using a fluorescence 
microscope, a single cell incubated in FITC-HA + PG (panel B) is shown next to a cell incubated 
with undecorated FITC-HA (panel C).  The fluorescence was quantified using Nis-elements 
software to acquire the mean pixel intensities for the two samples (shown below images).  Bars 
represent 20 µm. 
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Figure 18:  Effect of aggrecan on HA endocytosis   
RCS cells grown in chamber slides were treated with 200 TRU/ml bovine testicular 
hyaluronidase, washed extensively and then incubated for 24 h at 37 oC in control medium 
(Blank; Panels A and B), medium containing FITC-HA alone (HA; panels C and D) or, FITC-
HA + aggrecan aggregates (HA+PG; panels E and F).  The washed cells were then treated with 
Streptomyces hyaluronidase (S. HA’ase; panels A, C and E) or trypsin (panels B, D and F) to 
remove all extracellular-localized glycosaminoglycan.  The S. HA’ase treated cells were 
additionally fixed and mounted in medium containing DAPI nuclear stain.  Both S. HA’ase and 
trypsin-treated cells were visualized by fluorescence microscopy.  Shown are digital overlay 
images of green (HA) and blue (nucleus) fluorescence channels.   Images shown are 
representative experiments from 8 independent experiments with S. HA’ase post-treatment; 3 
independent experiments performed with trypsin post-treatment.    All bars are 20 µm.   Mean 
pixel intensity of 25-30 cells per each experimental condition were evaluated for experiments 
with post-treatment by S. HA’ase (panel G) or trypsin (panel H).  Shown are the box plots of 
mean pixel intensities in RCS cells treated with FITC-HA without (-) or with (+) the inclusion of 
purified aggrecan.  Mean pixel intensities of cells recorded as outliers are included and shown as 
dark round circles (•).  The bar graph in Panel I represents the mean pixel intensity average ± SD 
of 8 independent experiments with S. HA’ase post-treatment and is illustrated as the normalized 
percent change in mean pixel intensity of HA+PG treated cells (+) as compared to RCS cells 
treated with HA alone (-) set to 100%.  Asterisks denote p-value < 0.05. 
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Figure 19:  Limited C-terminal cleavage of aggrecan with clostripain protease   
Aggrecan, either as a free monomer (panels A and B) or in an aggregate bound to HA (panels C 
and D), was digested for 0-30 minutes with clostripain protease and then evaluated directly by 
electrophoresis on 1% agarose gels stained with DMMB.   Individual clostripain-digested 
monomer fractions (as in panel A) were next incubated with HA to reconstitute aggregates and 
re-evaluated on agarose gels (panel B).    Individual clostripain-digested aggregate fractions (as 
in panel C) were subsequently treated with Streptomyces hyaluronidase to degrade the HA and 
return the aggrecan to monomers and re-evaluated on agarose gels (panel D).   Shown are 
representative images from 4 experiments.  A 1 kb DNA ladder standard (S) was used for 
reference and alignment of the gel.   
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Figure 20:  Effect of limited C-terminal cleavage of aggrecan on HA endocytosis 
Panel A depicts UV transilluminator imaging of FITC-HA alone (HA) or FITC-HA combined 
with 0, 10, 40 and 60 minute clostripain-digested aggrecan monomers following agarose gel 
electrophoresis.   Each fraction was then added individually (panels B-G) to hyaluronidase pre-
treated RCS cells for 24 hours at 37 oC followed by post-treatment with Streptomyces 
hyaluronidase.  Thus all images depict intracellularly-localized FITC-HA.  All bars are 20 µm.   
High power images of individual cells are shown as insets.  Mean pixel intensity of 25-30 cells 
per each experimental condition (HA alone; or HA + aggrecan treated with clostripain (CP) for 
0-60 minutes, HA+PG) were evaluated (panel H).  Shown are the box plots of mean pixel 
intensities from RCS cells that accumulate intracellular FITC-HA following addition of HA 
alone (HA) or various HA+PG preparations including control, untreated cells (Blank, designated 
B).  Mean pixel intensities of cells recorded as outliers are included and shown as dark round 
circles (•).  Student t-test comparisons were performed on HA alone condition and each of the 
HA+PG conditions; asterisks denotes p-value < 0.05.  The next set of experiments tested 
endocytosis of HA + aggrecan with clostripain treatment of 0 to 30 minutes.  RCS cells were 
incubated with HA alone (panel I), with HA+ intact PG (panel J), and then with HA + 
clostripain-treated PG:  5 minute treatment (panel K), 10 minute treatment (panel L), 15 minute 
treatment (panel N), 20 minute treatment (panel O), and 30 minute treatment (panel P).  All bars 
are 20 µm.   Mean pixel intensity of 25-30 cells per each experimental condition (HA alone; or 
HA + aggrecan treated with clostripain (CP) for 0-30 minutes, HA+PG) were evaluated (panel 
Q).  Shown are the box plots of mean pixel intensities in RCS cells that accumulate intracellular 
FITC-HA following addition of HA alone (HA) or various HA+PG preparations including 
control, untreated cells (Blank, panel M).  The bar graph in Panel R represents the mean pixel 
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intensity average ± SD of 2 independent experiments and is illustrated as the normalized percent 
change in mean pixel intensity of HA + clostripain-treated PG (for 0 – 30 minutes) as compared 
to RCS cells treated with HA alone (set to 100%).  Asterisks denote p-value < 0.05.  Panel S 
represents the mean pixel intensity average ± SD of 2 independent experiments and is illustrated 
as the normalized percent change in mean pixel intensity of HA + clostripain-treated PG (for 
only 0 – 10 minutes) as compared to RCS cells treated with HA alone (set to 100%).   Inset in 
panel S depicts the migration of aggrecan after digestion for 0-10 minutes with clostripain 
protease (CP). 
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Figure 21:  Effect of HA size on HA endocytosis   
Endocytosis of FITC-HA by RCS cells (panel B) was compared to endocytosis of FITC-HA 
following sonication for:  5 seconds (panel C), 10 seconds (panel D), 15 seconds (panel E), 20 
seconds (panel F), 25 seconds (panel G) or 30 seconds (panel H).  Panels A and L depict RCS 
cells with no addition. All bars are 20 µm.    Panel I depicts UV transilluminator-dependent 
imaging of FITC-HA by agarose gel electrophoresis following sonication for 0 – 30 seconds.  
Mean pixel intensity of 25-30 cells per each experimental condition (FITC-HA sonicated for 0-
30 seconds) were evaluated (panel J).  Shown are the box plots of mean pixel intensities in RCS 
cells that accumulated intracellular FITC-HA.  The bar graph in Panel K represents the mean 
pixel intensity average ± SD of 4 independent experiments and is illustrated as the normalized 
percent change in mean pixel intensity of FITC-HA + sonication (for 5-30 seconds) as compared 
to RCS cells incubated with non-sonicated FITC-HA (set to 100%).  Asterisks denote p-value < 
0.05.  Intact aggrecan monomer was combined with FITC-HA that had been sonicated for 
varying times, added to RCS cells and processed to visualize FITC-HA internalization; 
sonication times were 0 seconds (panel M), 5 seconds (panel N), 10 seconds (panel O), 15 
seconds (panel P), 20 seconds (panel Q), 25 seconds (panel R) and 30 seconds (panel S).  All 
bars are 20 µm.   The combination of intact aggrecan with intact FITC-HA (0) as well as with 
FITC-HA sonicated for 5 - 30 seconds was observed under UV following agarose gel 
electrophoresis (panel T).  Mean pixel intensity of 25-30 cells per each experimental condition 
(FITC-HA sonicated for 0-30 seconds) were evaluated (panel U).  Shown are the box plots of 
mean pixel intensities in RCS cells that accumulated intracellular FITC-HA.  The bar graph in 
Panel V represents the mean pixel intensity average ± SD of 4 independent experiments and is 
illustrated as the normalized percent change in mean pixel intensity of FITC-HA + sonication 
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(for 5-30 seconds) as compared to RCS cells incubated with FITC-HA alone (set to 100%).  
Asterisks denote p-value < 0.05. 
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Figure 22:  Effect of C-terminal cleavage of aggrecan on HA/aggrecan endocytosis  
Aggrecan core protein was labeled with dansyl chloride as a blue fluorescent marker.  Panel A 
shows low autofluorescence of RCS cells in the blue channel (Blank).  RCS cells were then 
incubated with HA + intact dansyl-PG (panel B) or with HA + dansyl-PG treated with clostripain 
for 30 minutes (panels D and E). Similarly, intact dansyl-PG was allowed to re-aggregate with 
15 second sonicated HA and added to RCS cells (panel C).  All bars are 20 µm.   High power 
images of individual cells are shown as insets.   Size differences between intact dansyl-PG (0) 
and dansyl-PG treated with clostripain for 30 minutes (30ʹ′) were detected on 1% agarose gels 
stained with DMMB (panel F).  Dansyl-PG mixed with HA (panel G, lane 1) or HA sonicated 
for 15 seconds (panel G, lane 2) exhibited a size shift to the loading wells of the agarose gel; blue 
fluorescence detected by UV transillumination.  Dansyl-PG pretreated with clostripain for 30 
minutes and then combined with HA also exhibited a size shift (panel G, lane 3).   Mean pixel 
intensity of 25-30 cells per each experimental condition [Blank (B); HA + intact dansyl-PG (0); 
15 second sonicated HA + intact dansyl-PG (s0); HA + dansyl-PG treated with clostripain (CP) 
for 30 minutes (30)] were evaluated as a box plot (panel G).  Shown are the box plots of mean 
pixel intensities in the blue channel (dansyl chloride) that accumulated in RCS cells.  The bar 
graph in Panel H represents the mean pixel intensity average ± SD of 3 independent experiments.  
Asterisks denote p-value < 0.05.   
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Figure 23:  Detection of hyaluronidase activity on a cell monolayer 
High molecular mass FITC-HA (200 µg/ml) was added to the media of 4 cultures of C28/I2 
chondrocytes for 4 days (panel A, lanes marked 4d) and then visualized on a 1% agarose gel and 
detected under ultraviolet light (panel A).  The samples were compared to a blank FITC-HA 
(panel A, lane marked B) that was incubated for four days in the absence of a cell monolayer.   
Panel B depicts quantification of the fluorescent intensity of the entire length of the lanes in the 
agarose gel using Quantity One software of the control sample (red line) compared to the four 
samples treated for four days.  The pixel intensity is depicted in the y-axis and the Rf value in the 
x-axis.  Panel C is a graph depicting the normalized mean fold-change migration (y-axis) of the 
FITC-HA cleavage observed when incubated on a monolayer of C28/I2 cells (96 hr) compared to 
a FITC-HA blank sample in the absence of cells (B).   Image is a representative of 2 separate 
experiments.   
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Figure 24:  Detection of hyaluronidase activity at pH 6.8 
Aliquots of FITC-HA (200 µg/ml) were incubated at 37oC at pH 6.8 for 24, 48, 72, and 96 hours 
with CD44/HYAL-2 Dynabead complexes (panel A, lanes 3), control Dynabeads (panel A, lanes 
2) or FITC-HA blank samples in pH 6.8 buffer (panel A, lanes 1). Panel A depicts samples on 
1% agarose gels and visualized under ultraviolet light.  Panels B-E depict chromatographs of 
pixel intensities of the entire length of the lanes in the agarose gels using Quantity One software 
to quantify the blank FITC-HA samples (red lines), control Dynabeads (green lines), and 
CD44/HYAL-2 Dynabeads (yellow lines).  The pixel intensity is depicted on the y-axis and the 
Rf value on the x-axis. Panel F depicts a graph of the normalized mean fold-change migration (y-
axis) of the FITC-HA cleavage observed when incubated with CD44/HYAL-2 Dynabeads 
(hatched bars) and FITC-HA incubated with control Dynabeads (solid black bars), compared to a 
blank FITC-HA sample (B).  * p < 0.05, ** p < 0.01 for comparison of CD44/HYAL-2 
Dynabead complexes to control Dynabead complexes.  Panel depicts one representative 
experiment from a set of three individual experiments.   
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Figure 25:  Detection of hyaluronidase activity at pH 4.8 
FITC-HA (200 µg/ml) was incubated at 37oC at pH 4.8 in 24 hour intervals with CD44/HYAL-2 
Dynabead complexes (panel A, lanes 2) or FITC-HA alone in pH 4.8 buffer (panel A, lanes 1).  
Panel A depicts samples on 1% agarose gels and visualized under ultraviolet light.  Panels B-E 
depict chromatographs of pixel intensities of the entire length of the lanes in the agarose gels 
using Quantity One software to quantify the blank FITC-HA sample (red lines) and 
CD44/HYAL-2 Dynabeads (green lines).  The pixel intensity is depicted on the y-axis and the Rf 
value on the x-axis. Panel F depicts a graph of the normalized mean fold-change migration (y-
axis) of the FITC-HA cleavage observed when incubated with CD44/HYAL-2 Dynabeads 
(hatched bars) compared to a blank FITC-HA sample (B).  Panel depicts one representative 
experiment from a set of two individual experiments.   
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Figure 26:  Detection of hyaluronidase activity using biotin-HA ELISA 
A high affinity ELISA plate was coated overnight with a serial dilution of biotinylated 
hyaluronan (biotin-HA) for detection with streptavidin-HRP and substrate reagent.   In parallel 
wells was added control buffer (red bars) or a suspension of a sonicated membrane fraction 
derived from primary bovine articular chondrocytes (blue bars) added at a fixed membrane 
protein concentration of 100 µg/well, and incubated for 3 hours at pH 6.8.  Graph is a 
representative experiment from a set of 4 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
CHAPTER 4:  GENERAL DISCUSSION AND CONCLUSIONS 
 
Chondrocytes and many cell types exhibit large, HA-dependent pericellular matrices 
(17,18).  When these matrices are removed, the addition of exogenous HA together with 
aggrecan can rapidly re-establish these pericellular coats even on non-living, fixed cells 
(17,18,51).   All that is required is a HA receptor such as CD44, HA and aggrecan.  We have also 
shown that CD44 mediates the endocytosis of HA as well as the co-internalization of bound 
aggrecan G1 domains including G1-ITEGE and G1-DIPEN (4,7-9).   It has been of interest to 
determine how cells such as chondrocytes regulate the seemingly opposite functions of CD44 
and HA namely, HA-rich pericellular matrix retention and HA-matrix turnover.   These cell 
surface events extend out to the tissue wherein proteoglycans such as aggrecan are enzymatically 
processed within the extracellular matrix with end products diffusing out of the tissue.  HA on 
the other hand has a mechanism available for local, receptor-mediated endocytosis.  Some 
investigators suggested that HA diffusion from cartilage could be substantial (52,53) whereas 
others have estimated that diffusion accounts for 9% of total HA lost from cartilage (15).   It 
remains necessary to determine a mechanism to explain why the turnover half-life of newly 
synthesized HA and aggrecan in cartilage explants is nearly identical (15,33).   The results of this 
study address this mechanism.  
 
One clear observation of this study is that the binding of intact aggrecan monomer to high 
molecular weight HA results in a nearly complete blockage of HA endocytosis.  This suggests 
that little local turnover of HA occurs in vivo until some degree of aggrecan processing has 
occurred.  The second important observation was that a reduction in the size of the aggrecan 
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monomer, by seemingly modest size changes, removes the proteoglycan impediment to HA 
endocytosis.   The HA itself may also become degraded within the extracellular environment by 
hyaluronidases or free radicals (14).  Nonetheless, if the shortened HA length is sufficient to bind 
a particular number of aggrecan monomers (as in Figure 21N, 21O), HA internalization will 
continue to be blocked.   Thus, it is the release from the aggrecan block that is the likely 
mechanism responsible for nearly equivalent turnover half-lives of aggrecan and HA (15,33).   
Moreover, such a mechanism would facilitate either mode of HA turnover, local endocytosis or 
diffusion out of the tissue.  We do not know whether the same inhibition of HA endocytosis 
occurs with other aggregating proteoglycans such as versican (54-58), neurocan or brevican (59-
61) but would predict their inhibitory potential would be dependent on the size, charge or cross-
linking domains uniquely associated with these proteoglycans.   
 
The overall size and/or charge of large macromolecules such as aggrecan is the likely 
mechanism responsible for the blockage of HA endocytosis.   Each aggrecan monomer bound to 
HA has a molecular mass > 106 Daltons (62).  With limited C-terminal cleavage of aggrecan, a 
break point in blocking capacity appears between 10 and 15 minutes of clostripain digestion of 
aggrecan (Figure 20D, 21L, 21N, 21R).   A significant jump in HA endocytosis was observed 
when FITC-HA was decorated with the 15 minute digested monomer.  In fact, the endocytosis 
associated with this condition was not significantly different from FITC-HA with no aggrecan 
bound (Figure 20B).  The 15 minute digested aggrecan does appear slightly more degraded than 
the monomer treated for 10 minutes (Figure 19A) but the change in migration on agarose gels, 
from 0-30 minutes of digestion is gradual (Figure 19A) exhibiting no major jump in size between 
the 10 and 15 minute preparations.  Moreover, all aggrecan fractions between 0-30 minutes 
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readily formed reconstituted aggregates with HA (Figure 19B).   Thus, although we do not (and 
likely will never) know the exact cut-off size of aggrecan that inhibits or is permissive for HA 
endocytosis, it is clear that such a size exists.     
 
Another method to investigate the restrictions of HA endocytosis based on size was to 
generate HA chains shortened by sonication.  This was performed to mimic extracellular HA 
fragmentation (114).  Possible sources of extracellular HA fragmentation can include free radical 
degradation by reactive oxygen species (91,114) or HYALs (3,4), but it is unclear exactly how 
this happens (thus leading to neutral pH HYAL-2 studies).  FITC-HA endocytosis was enhanced 
proportional to the length of sonication time (Figure 21C-H).   It has long been known that 
shorter HA chains are internalized more efficiently than high molecular mass HA (66) but it is 
also clear that intact HA (>106 Da) is internalized directly without extracellular processing (4). 
Nonetheless, the point of these experiments was to demonstrate that size matters, including the 
size of the HA itself with no aggrecan bound.   There are no precise data for the exact size of the 
sonicated HA fractions other than noted by changes in migration on 1% agarose gels. However, 
the profile of these sonicated preparations, as shown in Figure 21I, are sizes within the range of 
middle molecular mass HA shown in Figure 9A, 9B.  Again, the precise size is not as critical as 
the functional size.  The addition of intact aggrecan monomer to sonicated HA resulted in the 
formation of HA+PG aggregates except for HA sonicated longer than 20 seconds (Figure 21T).   
One interpretation is that the HA sonicated longer than 20 seconds was too short to allow 
aggrecan binding.   Nonetheless, the goal of this approach was to observe the effects of aggrecan 
on a HA species that was sufficiently short such that it could only support the binding of a 
minimal number of intact aggrecans, perhaps even a single monomer.   Our best model of such a 
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species is the 15 second sonicated HA+PG aggregate.  Although clearly a HA+PG aggregate 
(Figure 21T), this complex was permissive for HA endocytosis (Figure 21P), whereas the 10 
second sonicated HA+PG preparation (also an aggregate, Figure 21P) blocked HA endocytosis 
(Figure 21O).   We propose that the 10 second sonicated HA+PG aggregate is long enough to 
retain multiple aggrecan monomers, while the 20 second sonicated HA is incapable of binding 
any aggrecan.   Together the data suggest that there is an overall size limit for HA+PG 
aggregates that is restrictive for HA endocytosis.  These results also demonstrated that it is 
possible that HA with one or a few bound intact aggrecan monomers (as in Figure 21P), is not 
blocked from undergoing endocytosis.  However, the latter conclusion would imply that the 
aggrecan itself is being co-internalized with the HA.  As an alternative explanation, sufficient 
FITC-HA not sequestered into an HA+PG aggregate could contribute to the high level of 
internalized HA observed in Figure 21P.   
 
To address this question, aggrecan was fluorescently labeled with dansyl chloride	  
(42,43), a conjugation that did not interfere with HA binding (Figure 22G).  Following the 
addition of HA combined with 30 minute clostripain-digested dansylated PG to RCS cells; blue 
fluorescent intracellular vesicles were observed (Figure 22D, 22E).  Previously, co-
internalization of HA and aggrecan G1 domains was observed (7-9); however these small 
globular domains carry little substitution with chondroitin sulfate or keratan sulfate as would be 
represented by the strongly DMMB positive band shown in Figure 22F or shift with HA into the 
load well of an agarose gel (Figure 19B).   Thus, RCS cells can internalize partially degraded 
aggrecan.   Given that no aggrecan receptor has ever been documented and given this preparation 
forms an HA+PG aggregate (Figure 19B) we propose that the dansylated proteoglycan was co-
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internalized with HA.  Faint, but discernable intracellular blue fluorescence was also observed 
when HA+PG aggregates were prepared with intact dansylated aggrecan mixed with 15 second 
sonicated HA (Figure 22C).    Although this may represent the internalization of a single or few 
intact aggrecan monomers, we are more cautious about this point.  It remains a possibility that 
during the 24 hour incubation period, endogenous proteinases, released into the culture medium, 
sufficiently degraded the dansylated aggrecan so as to allow its endocytosis as was observed in 
Figure 22D, 22E.  Nonetheless, a straightforward conclusion is that it is overall size that matters 
with regard to HA endocytosis.  For example, it is likely that an HA chain in vivo is decorated 
with a combination of partially fragmented and intact PG monomers, thus internalization will not 
be permitted until an overall threshold size of the aggregate is achieved.      
 
CD44 itself undergoes co-internalization with HA endocytosis (67,68).  In fact, HA itself 
is an impediment to CD44 endocytosis. HA+PG depleted bovine chondrocytes internalize / cycle 
20% of their cell surface CD44 intracellularly within a 4 hour period whereas only 6% is 
internalized when the CD44 is occupied with HA (67). As such, one can speculate on another 
biological significance of aggrecan impendence of HA (and CD44) endocytosis.  CD44 has been 
shown to interact and co-immunoprecipitate with several signaling receptors including EGF and 
TGFβ receptors (69-71).  HA+PG aggregates bound to CD44 would limit the 
endocytosis/cycling of CD44 as well as any receptors tethered to CD44.   Extracellular protease 
cleavage of aggrecan would release the HA endocytosis block and result in HA-CD44 
endocytosis and permit kinase receptor turnover.  
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In this study we have demonstrated the usefulness of visualizing highly poly-disperse 
matrix macromolecules such as HA and aggrecan using agarose gel electrophoresis.  This 
technique provided an effective way to observe the shift in size of HA and aggrecan when the 
two components are allowed to re-aggregate and to view the fragmentation of these two 
following sonication or enzymatic cleavage.   Stains-All detected HA (light blue), proteoglycans 
(dark-blue to purple) and the DNA standards (Figure 11A).  DMMB was more selective by 
marking the sulfated proteoglycans as reddish blue-pink bands depending on the amount of 
background destaining, while HA by itself was not stained (Figure 11B).   Interestingly, HA+PG 
aggregates were purple with DMMB staining (Figure 13B, Figure 19B, 19C) although this could 
be due to the clustering of proteoglycans on HA during the formation of aggregates.  This is the 
first application, to our knowledge, of the dye DMMB being used to stain agarose gels; typically 
it is used as a chlorimetric agent in a DMMB assay to quantify sulfated glycosaminoglycans.  
The 1000 bp incremented DNA standards were useful to normalize aggrecan migration patterns 
from experiment to experiment.  The intact aggrecan monomer typically migrated between the 
3000 and 6000 bp standard bands.   
 
Certain complications can arise when introducing exogenous material (FITC-HA) to a 
living system (RCS cells).  One critical complication is that the RCS cells are internalizing the 
FITC-HA and degrading it.  This makes it difficult to visualize a change in internalization of HA 
when the material with the fluorescent probe is being turned over and lost from the cell.  At any 
time point, the FITC-HA that is observed within the cell is a snapshot of a dynamic process of 
accumulation in the wake of active degradation.  To address this complication, cells were 
incubated with chloroquine, a lysosomal activity inhibitor.  By preventing lysosomal activity, all 
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internalized HA would accumulate and be represented.  In chloroquine-treated chondrocytes, the 
intracellular intensity of internalized FITC-HA was higher at every time point investigated as 
compared to non-chloroquine treated cells (data not shown).  However, the presence or absence 
of chloroquine did not alter the overall results of this study.  For example, the inhibition of FITC-
HA endocytosis in the presence of aggrecan occurred in cells with or without chloroquine 
treatment.  Nonetheless, the measurement of FITC-HA intracellular accumulation alone (without 
ongoing degradation) improved the consistency of the results and represented an advancement 
over previous studies investigating HA internalization in the Knudson laboratory that had not 
included the use of chloroquine (106,107).   
 
Another possible complication of this study was the time duration the RCS cells were 
allowed to bind and internalize FITC-HA.  Preliminary studies were performed using varying 
incubation times consisting of 3, 6, 12, and 24 hours to investigate and monitor the capacity of 
the RCS cells to internalize HA.  The early time points were useful due to less complications and 
competition by the re-growth of endogenous HA and aggrecan but, the amount of intracellular 
FITC-HA that accumulated was low and difficult to quantify.  The longer time point of 24 hours 
provide for higher pixel intensities of the internalized FITC-HA and the results were more 
readily quantifiable and consistent from experiment to experiment.  The drawback of the 24 hour 
incubations with HA and HA+PG was the possibility that the RCS cells produced endogenous 
PG that could bind the undecorated FITC-HA, and thus hinder its internalization or slow down 
the internalization of HA decorated with clostripain digested PG.  Additionally, endogenous HA 
was also being produced by the RCS cells during this time period, potentially competing with the 
fluorescently labeled HA for binding to CD44.  Nonetheless, considering that data collected at 
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the 24 hour time points were more consistent, reliable, and quantifiable, this time point was 
chosen for the major part of these studies.  It is possible that even more FITC-HA alone (the 
positive control) could be internalized at the 24 hour time point if future experiments included a 
knock-down of endogenous HA and aggrecan synthesis.  Another possible limitation of our 
results (already discussed above) is that RCS cells have the potential to produce and release into 
the medium, endogenous aggrecan degrading enzymes, thus expediting internalization of HA 
decorated with intact PG.  Release of such endogenous proteolytic activity could be responsible 
for the background levels of intracellular FITC-HA observed when FITC-HA + PG are added to 
RCS cells (Figure 18E, 18F).     
  
Clostripain digestion of aggrecan at time points shorter than 10 minutes resulted in HA 
endocytosis at a substantially reduced level (Figure 20K, 20Q-S).  Interestingly, clostripain 
digestion even as short as 2 minutes of exposure resulted in an increase in HA endocytosis that 
was statistically significant above intact aggrecan-containing aggregates (Figure 20J vs. 20K).   
One possibility to explain these results is that some important protein domain present on 
aggrecan is removed during the early time periods of clostripain digestion such as the removal of 
the C-terminal globular G3 domain of the aggrecan core protein.  It has long been suggested that 
the globular G3 domain participates in cross-linking of aggrecan monomers (63).  This 
interaction would allow pericellular coats to grow as wide as one cell diameter.  For example, the 
globular G3 domain of aggrecan has been shown to cross-link with other aggrecan globular G3 
domains via tenascin-C (63) (Figure 27).  It is not known whether the RCS cells used in this 
study synthesize sufficient tenascin-C or some other crosslinking species that would promote 
such cross-links.  However, the RCS cells do assemble pericellular coats with exogenously 
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added aggrecan (Figure 13E).  Future studies will be needed to determine whether the aggrecan 
used in this study (purified from the cartilage of young cattle) retains the globular G3 domain 
and, whether this globular G3 domain was lost by short-term clostripain digestion as in Figure 
20S.  Nonetheless, the loss of an aggrecan cross-linking domain could provide an additional 
mechanism to relieve the HA endocytosis block.  It should also be noted that during the aging 
process, cartilage aggrecan becomes reduced in size, including the proteolytic loss of globular 
G3 domains, shortening of the core protein and, shortening of chondroitin sulfate chains during 
biosynthesis (64,65).  This age related loss of tenascin-C binding sites in the ECM could explain 
the findings from previous investigators that tenascin-C is weakly expressed in adult cartilage 
(143).  Aggrecan in mature cartilage would have a decreased ability to cross-link with other 
ECM proteoglycans, thus preventing the cross-linking of large HA/aggrecan aggregates that are 
resistant to turnover.  It can be predicted that HA turnover would be more prominent with age, 
thus making OA onset more likely.  Interestingly, other studies have shown that tenascin-C, 
while weakly present in adult cartilage, is upregulated in OA cartilage, thus suggesting a possible 
repair mechanism by crosslinking aggrecan in an attempt to rebuild the cartilage ECM (144,145).   
 
Cell-associated HA is most likely turned over by CD44-mediated internalization, and 
degraded in low pH vesicles.  This study has mainly focused on the extracellular fragmentation 
of aggrecan to promote HA internalization.  A complementary mechanism for this turnover 
pathway may include extracellular processing of HA.  The extracellular fragmentation of cell- 
associated HA may be another means for decreasing the steric hindrance of the HA/aggrecan 
aggregate, such as the conditions displayed in Figure 21.  A series of experiments were 
performed to investigate the feasibility for HYAL-2, a lysosomal hyaluronidase, to cleave HA in 
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conditions that mimic the ECM.  Co-immunoprecipitation of HYAL-2 via CD44 was a useful 
method to purify HYAL-2, as well as selectively purifying HYAL-2 that is bound to CD44.  
Sonicated membrane fractions of cells containing HYAL-2 and CD44 in the plasma membrane 
were also used, but the amount of cell particulate matter proved to be too confounding to the 
assays.  HYAL-2 activity was monitored using a variety of methods; the most successful 
approach involved resin beads bound with CD44/HYAL-2 complexes incubated with FITC-HA 
at varying pH ranges (Figures 24 and 25).  Subsequent reduction in size of the FITC-HA was 
detected by 1% agarose gel electrophoresis.  Additional methods involving ELISA assays 
showed promise but contained too many pitfalls (Figure 26).  Additionally, media containing 
FITC-HA incubated on a confluent monolayer of C28/I2 chondrocytes for four days exhibited no 
reduction in HA size  (Figure 23).  A weak but noticeable reduction in FITC-HA size was 
apparent in assays involving CD44/HYAL-2 Dynabead complexes incubated at pH 6.8 (Figure 
24).  Lowering the pH to 4.8 increased the enzymatic activity of HYAL-2 (Figure 25), which is 
in agreement with a previous investigation (4).  This suggests that HYAL-2 is capable of 
cleaving HA in conditions outside a lysosome when maintaining its interaction to CD44.  
 
    Future investigations can use the findings from this project to study a variety of 
mechanisms involved in OA.  One example is interleukin-1, a destructive cytokine, which is 
upregulated in early OA and has an inhibitory effect on PG production in chondrocytes.  
Additionally, interleukin-1 up regulates the expression of PG degrading enzymes such as MMPs.  
This combination of decreased PG production and increased PG turnover results in deterioration 
of the cartilage ECM.  Therefore, inhibiting interleukin-1 production would be a valuable tool to 
treat or prevent OA.  It has also been found that interleukin-1 up regulates CD44 expression and 
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endocytosis (141,142). Additionally, another investigator has shown that CD44, in turn, 
increases interleukin-1 expression when bound with low molecular weight HA, thus establishing 
a self perpetuating cycle of upregulation (128).  A possible solution to downregulate interleukin-
1 expression could be to decorate the CD44 bound, endogenous HA with intact, exogenous PG 
thus preventing the entire complex from being internalized.  This would stop CD44 from up 
regulating interleukin-1 and may return the chondrocytes to a state of equilibrium. Additional 
future investigations could follow CD44 internalization, instead of HA or aggrecan, when bound 
with intact HA/aggrecan aggregate compared to partially digested HA/aggrecan aggregate.    
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Figure 27:  Globular G3 domain mediated crosslinking of the aggrecan ECM 
Figure depicts possible mechanism for aggrecan crosslinking to another aggrecan monomer.  The 
blue icon represents an ECM protein such as tenascin-C that can bind to the C-lectin domain of 
the globular G3 domain, crosslinking it with another globular G3 domain on an aggrecan 
monomer.  Since these proteins can exist as multimers, several aggrecans can be crosslinked 
together.  HA is shown in brown, aggrecan core protein is black, and sulfated glycosaminoglycan 
chains in red. 
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